CA2220853A1 - Human lymphoid protein tyrosine phosphatases - Google Patents
Human lymphoid protein tyrosine phosphatases Download PDFInfo
- Publication number
- CA2220853A1 CA2220853A1 CA 2220853 CA2220853A CA2220853A1 CA 2220853 A1 CA2220853 A1 CA 2220853A1 CA 2220853 CA2220853 CA 2220853 CA 2220853 A CA2220853 A CA 2220853A CA 2220853 A1 CA2220853 A1 CA 2220853A1
- Authority
- CA
- Canada
- Prior art keywords
- lyp
- lyp2
- protein
- gene
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 title description 38
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 title description 36
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 176
- 108090000623 proteins and genes Proteins 0.000 description 139
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 136
- 102000004169 proteins and genes Human genes 0.000 description 96
- 235000018102 proteins Nutrition 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 81
- 239000002299 complementary DNA Substances 0.000 description 57
- 230000014509 gene expression Effects 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 47
- 238000000034 method Methods 0.000 description 35
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 30
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 30
- 239000013615 primer Substances 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 28
- 239000002773 nucleotide Substances 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 24
- 210000004698 lymphocyte Anatomy 0.000 description 23
- 239000012634 fragment Substances 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 230000000692 anti-sense effect Effects 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 210000004899 c-terminal region Anatomy 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 210000000349 chromosome Anatomy 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000003197 catalytic effect Effects 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 102000044914 human PTPN22 Human genes 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 108020004635 Complementary DNA Proteins 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000007901 in situ hybridization Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000003563 lymphoid tissue Anatomy 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 102000000395 SH3 domains Human genes 0.000 description 5
- 108050008861 SH3 domains Proteins 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 230000030570 cellular localization Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 101150084750 1 gene Proteins 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 108010015793 Non-Receptor Type 6 Protein Tyrosine Phosphatase Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 108020004491 Antisense DNA Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010021466 Mutant Proteins Proteins 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108010032109 Non-Receptor Type 12 Protein Tyrosine Phosphatase Proteins 0.000 description 3
- 102000002001 Non-Receptor Type 6 Protein Tyrosine Phosphatase Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000003816 antisense DNA Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000030609 dephosphorylation Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000002741 palatine tonsil Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102100033020 Tyrosine-protein phosphatase non-receptor type 12 Human genes 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 2
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 108020001778 catalytic domains Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000008711 chromosomal rearrangement Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000011820 transgenic animal model Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 101100522278 Caenorhabditis elegans ptp-1 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001041236 Mus musculus Ornithine decarboxylase Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000007603 Non-Receptor Type 12 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 101710116223 Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004952 blastocoel Anatomy 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007854 ligation-mediated PCR Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009392 systemic autoimmunity Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- -1 therapeutic drugs Substances 0.000 description 1
- 229940124788 therapeutic inhibitor Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Description
Human Lymphoid Protein Tyrosine Phosphatases Field of the Invention This invention relates to a human non-receptor protein tyrosine phosphatase (LyP 1 ) and an isoform of LyP 1, called LyP2. More particularly, it relates to the cDNA sequence of human LyP 1 and LyP2, the protein products and the expression and role of these phosphatases in humans.
Background of the Invention Protein tyrosine phosphorylation, a key mechanism of cellular signal transduction, is regulated by the action of both protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPases). Originally PTKs were believed to control the process of tyrosine phosphorylation, with a small number of PTPases playing largely housekeeping roles. Unexpectedly, the structural diversity of the growing number of PTPases has called this idea into question and it has become apparent that PTPases have important roles in the regulation of growth and differentiation in both normal and neoplastic cells (1,2). All PTPases contain a catalytic domain of approximately 200-300 residues including a subset of highly conserved amino acids that play a role in substrate recognition and tyrosine dephosphorylation (3).
The PTPases family can be divided broadly into two major classes: membrane bound receptor like, and non-receptor like or intracellular phosphatases (4,5). Both types can be further subdivided into subfamilies based on their sequence similarities and non-catalytic domain structure motifs (6,7).
The receptor PTPases contain one or two intracellular phosphatase domains and often Ig-like domains and fibronectin-like extracellular regions (6) that play a role in cell-cell or cell-matrix interactions (8). In fact, some receptor PTPases appear to participate in homophilic and heterophilic binding interactions suggestive of a role in cell guidance and contact inhibition (7,8).
The non-receptor phosphatases display various intracellular localizations determined by amino acid sequences outside the catalytic domain (9, 35, 40).
Some contain conserved non-catalytic domains such as the Src homology 2 (SH2) and domains allowing them to interact with a variety of tyrosine phosphorylated proteins and proteins containing proline rich sequences ( 10, 11 ). Cytoplasmic PTPases have been found associated with a variety of PTKs including CSK and the Jak kinases, and a number of cytokine and antigen receptors (7, 11,31).
Several lines of evidence indicate that within the immune system, PTPases are essential for lymphocyte development and activation. CD45, a transmembrane phosphatase expressed exclusively in hematopoietic cells (12), is required for antigenic activation of B and T lymphocytes (13, 14). In addition, evidence from CD45-deficient mice indicates that CD45 also plays a pivotal role in thymic development and T cell apoptotic response to T cell receptor engagement ( 15, 16).
Recent studies have suggested that the hematopoietic-specific intracellular phosphatase-SHP 1 (SH2 containing PTPase) negatively regulates signaling through association with the B cell receptor, PcyRIIB 1 ( 17) and the IL-3 receptor 3 chain ( 18).
SHP 1 also participates in T cell signalling events through dephosphorylation of the T
cell receptor (TCR), p561~k and ZAP-70 (19). Mutations in the marine motheaten locus coding the SHP 1 protein result in severe combined immunodeficiency and systemic autoimmunity, as well as many other hematopoietic abnormalities (20).
Furthermore, expression of HePTP, a cytoplasmic hematopoietic specific PTPase, is induced in lymphocytes stimulated by phytohemagglutinin, concavalin A, lipopolysaccharide and anti-CD3 (21 ), suggestive of a role in lymphocyte activation pathways. Together, these studies suggest a critical role for phosphatases in the development of the immune system.
Summary of the Invention A human gene encoding a non-receptor phosphatase predominantly expressed in lymphoid cells has been identified and designated Lymphoid Protein Tyrosine Phosphatase (LyPI ) gene. In addition, an isoform of LyPI has also been identified and designated LyP2. This isoform is a product of C-terminal alternative RNA
splicing resulting in a protein which is 116 amino acids shorter than LyP 1 and contains an alternative C-terminal of seven amino acids. The LyP gene is located on chromosome 1 p 13. The cDNA sequences encoding for LyP 1 and LyP2 have been cloned, sequenced and expressed to provide the respective proteins. The proteins are
Background of the Invention Protein tyrosine phosphorylation, a key mechanism of cellular signal transduction, is regulated by the action of both protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPases). Originally PTKs were believed to control the process of tyrosine phosphorylation, with a small number of PTPases playing largely housekeeping roles. Unexpectedly, the structural diversity of the growing number of PTPases has called this idea into question and it has become apparent that PTPases have important roles in the regulation of growth and differentiation in both normal and neoplastic cells (1,2). All PTPases contain a catalytic domain of approximately 200-300 residues including a subset of highly conserved amino acids that play a role in substrate recognition and tyrosine dephosphorylation (3).
The PTPases family can be divided broadly into two major classes: membrane bound receptor like, and non-receptor like or intracellular phosphatases (4,5). Both types can be further subdivided into subfamilies based on their sequence similarities and non-catalytic domain structure motifs (6,7).
The receptor PTPases contain one or two intracellular phosphatase domains and often Ig-like domains and fibronectin-like extracellular regions (6) that play a role in cell-cell or cell-matrix interactions (8). In fact, some receptor PTPases appear to participate in homophilic and heterophilic binding interactions suggestive of a role in cell guidance and contact inhibition (7,8).
The non-receptor phosphatases display various intracellular localizations determined by amino acid sequences outside the catalytic domain (9, 35, 40).
Some contain conserved non-catalytic domains such as the Src homology 2 (SH2) and domains allowing them to interact with a variety of tyrosine phosphorylated proteins and proteins containing proline rich sequences ( 10, 11 ). Cytoplasmic PTPases have been found associated with a variety of PTKs including CSK and the Jak kinases, and a number of cytokine and antigen receptors (7, 11,31).
Several lines of evidence indicate that within the immune system, PTPases are essential for lymphocyte development and activation. CD45, a transmembrane phosphatase expressed exclusively in hematopoietic cells (12), is required for antigenic activation of B and T lymphocytes (13, 14). In addition, evidence from CD45-deficient mice indicates that CD45 also plays a pivotal role in thymic development and T cell apoptotic response to T cell receptor engagement ( 15, 16).
Recent studies have suggested that the hematopoietic-specific intracellular phosphatase-SHP 1 (SH2 containing PTPase) negatively regulates signaling through association with the B cell receptor, PcyRIIB 1 ( 17) and the IL-3 receptor 3 chain ( 18).
SHP 1 also participates in T cell signalling events through dephosphorylation of the T
cell receptor (TCR), p561~k and ZAP-70 (19). Mutations in the marine motheaten locus coding the SHP 1 protein result in severe combined immunodeficiency and systemic autoimmunity, as well as many other hematopoietic abnormalities (20).
Furthermore, expression of HePTP, a cytoplasmic hematopoietic specific PTPase, is induced in lymphocytes stimulated by phytohemagglutinin, concavalin A, lipopolysaccharide and anti-CD3 (21 ), suggestive of a role in lymphocyte activation pathways. Together, these studies suggest a critical role for phosphatases in the development of the immune system.
Summary of the Invention A human gene encoding a non-receptor phosphatase predominantly expressed in lymphoid cells has been identified and designated Lymphoid Protein Tyrosine Phosphatase (LyPI ) gene. In addition, an isoform of LyPI has also been identified and designated LyP2. This isoform is a product of C-terminal alternative RNA
splicing resulting in a protein which is 116 amino acids shorter than LyP 1 and contains an alternative C-terminal of seven amino acids. The LyP gene is located on chromosome 1 p 13. The cDNA sequences encoding for LyP 1 and LyP2 have been cloned, sequenced and expressed to provide the respective proteins. The proteins are
2 most highly expressed in lymphoid tissues including spleen, lymph nodes, peripheral leukocytes, tonsil B and T lymphocytes and in bone marrow.
In accordance with one embodiment of the invention, an isolated nucleic acid is provided comprising a nucleotide sequence encoding human LyP 1 protein. The nucleic acid may be in the form of DNA, genomic DNA, cDNA, mRNA and various fragments and portions of the sequence encoding human LyPl.
In accordance with another embodiment of the invention, an isolated human gene which maps to chromosome lp 13 and encodes human LyP 1 protein.
In accordance with another embodiment of the invention, an isolated human gene which maps to chromosome 1p13 and encodes human LyP2 protein.
In accordance with a further embodiment of the invention, a purified nucleotide sequence is provided comprising genomic DNA, cDNA, mRNA, anti-sense DNA or homologous DNA corresponding to the cDNA sequence of Sequence ID
No.l.
In accordance with a further embodiment of the invention, is a purified nucleotide sequence sharing 95% homology to Sequence ID No.l and encoding human LyP 1 protein.
In accordance with a further embodiment of the invention is a substantially pure human LyP 1 protein. In accordance with a further embodiment is a protein comprising the amino acid sequence of Sequence ID No.2.
In accordance with another embodiment of the invention are protein fragments comprising at least 12 contiguous amino acids of Sequence ID No.2.
In accordance with a further embodiment of the invention is a purified protein sharing 95% homology to Sequence ID No.2 and having human LyPl activity.
In accordance with a further embodiment of the invention, a substantially pure polypeptide is provided comprising at least one functional domain of a human LyP 1 protein.
In accordance with a further embodiment of the invention, a substantially pure polypeptide is provided comprising an antigenic determinant of a human LyP 1 protein.
In accordance with another embodiment of the invention, an isolated nucleic acid is provided comprising a nucleotide sequence encoding human LyP2 protein.
The nucleic acid may be in the form of cDNA or mRNA and various fragments and portions of the gene sequence encoding human LyP2.
In accordance with a further embodiment of the invention, a purified nucleotide sequence is provided comprising cDNA, mRNA, anti-sense DNA or homologous DNA corresponding to the cDNA sequence of Sequence ID No.3.
In accordance with a further embodiment of the invention, is a purified nucleotide sequence sharing 95% homology to Sequence ID No.3 and encoding for human LyP 1 protein.
In accordance with a further embodiment is a substantially pure human LyP2 protein.
In accordance with a further embodiment of the invention is an amino acid sequence corresponding to the amino acid sequence of Sequence ID No.4.
In accordance with a further embodiment of the invention, a method is provided for altering the lymphoid cell differentiation pathway in which LyP 1 and/or LyP2 is active comprising administering to the cell an agent selected from the group consisting of;
(a) monoclonal or polyclonal antibodies specifically binding human LyP 1 or LyP2 protein;
(b) a polynucleotide antisense strand capable of hybridizing to human LyP 1 and gene or gene transcripts;
(c) an agent to alter phosphorylation of human LyP 1 or LyP2 protein;
(d) a composition comprising a mixture of (a) to (c).
In accordance with a further embodiment of the invention, a method is provided for identifying allelic variants or heterospecific homologues of a LyP 1 gene comprising (a) choosing a nucleic acid probe or primer capable of hybridizing to a human LyP 1 gene sequence under stringent hybridization conditions;
(b) mixing said probe or primer with a sample of nucleic acids which may contain a nucleic acid corresponding to the variant or homologue;
(c) detecting hybridization of the probe or primer to the nucleic acid corresponding to the variant of homologue.
In accordance with a further embodiment of the invention, a method is provided for producing antibodies which selectively bind to a human LyP 1 or LyP2 protein comprising the steps of administering an immunogenically effective amount of a human LyP 1 or LyP2 immunogen to an animal;
allowing the animal to produce antibodies to the immunogen; and obtaining the antibodies fiom the animal or fiom a cell culture derived therefrom.
In accordance with a further embodiment of the invention, a substantially pure antibody is provided which binds selectively to an antigenic determinant of a human LyP 1 or LyP2 protein.
In accordance with a further embodiment of the invention, a method is provided for identifying compounds modulating expression of a human LyP 1 gene comprising;
contacting a cell with a test candidate wherein the cell includes a regulatory region of a human LyPl gene operably joined to a coding region; and detecting a change in expression of the coding region.
In accordance with a further embodiment of the invention, a method is provided for altering T cell differentiation in lymphoid tissues, comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of an isolated antisense nucleotide sequence which hybridizes with human LyP 1 or LyP2 gene sequence; and a substantially pure monoclonal antibody which recognizes LyP 1 or LyP2 protein.
In accordance with a further embodiment of the invention, a pharmaceutical composition is provided comprising an active ingredient selected from the group consisting of an antisense sequence which hybridizes to a human LyP 1 nucleotide sequence or to a transcript of the sequence;
a substantially pure antibody which binds selectively to human LyP 1 or LyP2 protein and a pharmaceutically acceptable carrier;
a mimetic of human LyP 1 or LyP2 protein;
a functional analog of human LyPI or LyP2 protein;
an inhibitor of human LyP 1 or LyP2 protein activity; and an agent capable of altering the phosphorylation state of human LyP 1 or LyP2 protein.
In accordance with a further embodiment of the invention, a method is provided of screening for an agent useful in treating a disorder characterized by an abnormality in a phosphorylation signaling pathway of lymphoid cells, wherein the pathway involves an interaction between a human LyP 1 or LyP2 protein and a human LyP 1 or LyP2 activator, comprising screening potential agents for ability to disrupt or promote the interaction as an indication of a useful agent.
In accordance with a further aspect of the invention, a method is provided of preventing or treating a disorder in a mammal characterized by an abnormality in an intracellular phosphorylation signaling pathway of lymphoid cells, wherein the pathway involves an interaction between a human LyP 1 or LyP2 protein and a human LyP 1 or LyP2 substrate, comprising the step of disrupting or promoting said interaction in vivo.
In accordance with another aspect of the invention, a transgenic mouse model for various diseases involving abnormally activated lymphoid cells which comprises an animal which has in its genome a human gene encoding LyP mutated to manifest altered activation. The transgenic mouse may exhibit symptoms indicative of lymphoid cell disorders.
In accordance with another aspect of the invention, the LyP 1 or LyP2 protein can be used as a starting point for rational drug design to provide ligands, therapeutic drugs, inhibitors or other types of small chemical molecules.
Brief Description of the Drawings Certain embodiments of the invention are described, reference being made to the accompanying drawings, wherein:
Figure 1 shows a Schematic diagram of LyPl and LyP2 deduced from the cDNA clones. Boxes indicate the open reading frame, with thin lines representing the 5' and 3' untranslated regions. The six overlapping cDNA clones (bold black lines) obtained from a human thymus cDNA library are shown under the schematic structures of the cDNAs.
Figure 2 shows an alignment of LyPl and Z70PEP amino acid sequences. The PTPase domain is indicated by brackets. An arrow indicates the end of the amino acid sequence shared by LyP 1 and LyP2 and the beginning of the unique C-terminal sequence of LyP 1. The NXXY motif is indicated by line above the sequence. The four potential SH3 domain binding sites are also indicated (asterisks). A
consensus sequence is shown below the alignment.
Figure 3 demonstrates that LyP2 is a result of alternative splicing of the LyP
gene. A, schematic map of the PCR strategy used. Primer 1 corresponds to the last 20 nucleotides shared by both LyP 1 and LyP2 sequences, primer 2 to LyP2 untranslated area and primer 3 to the beginning of the novel LyP 1 sequence, immediately downstream of primer 1. (see also C). B. The results of the PCT
amplification on genomic DNA. Lane 1, DNA size markers, Lane 2, a product of
In accordance with one embodiment of the invention, an isolated nucleic acid is provided comprising a nucleotide sequence encoding human LyP 1 protein. The nucleic acid may be in the form of DNA, genomic DNA, cDNA, mRNA and various fragments and portions of the sequence encoding human LyPl.
In accordance with another embodiment of the invention, an isolated human gene which maps to chromosome lp 13 and encodes human LyP 1 protein.
In accordance with another embodiment of the invention, an isolated human gene which maps to chromosome 1p13 and encodes human LyP2 protein.
In accordance with a further embodiment of the invention, a purified nucleotide sequence is provided comprising genomic DNA, cDNA, mRNA, anti-sense DNA or homologous DNA corresponding to the cDNA sequence of Sequence ID
No.l.
In accordance with a further embodiment of the invention, is a purified nucleotide sequence sharing 95% homology to Sequence ID No.l and encoding human LyP 1 protein.
In accordance with a further embodiment of the invention is a substantially pure human LyP 1 protein. In accordance with a further embodiment is a protein comprising the amino acid sequence of Sequence ID No.2.
In accordance with another embodiment of the invention are protein fragments comprising at least 12 contiguous amino acids of Sequence ID No.2.
In accordance with a further embodiment of the invention is a purified protein sharing 95% homology to Sequence ID No.2 and having human LyPl activity.
In accordance with a further embodiment of the invention, a substantially pure polypeptide is provided comprising at least one functional domain of a human LyP 1 protein.
In accordance with a further embodiment of the invention, a substantially pure polypeptide is provided comprising an antigenic determinant of a human LyP 1 protein.
In accordance with another embodiment of the invention, an isolated nucleic acid is provided comprising a nucleotide sequence encoding human LyP2 protein.
The nucleic acid may be in the form of cDNA or mRNA and various fragments and portions of the gene sequence encoding human LyP2.
In accordance with a further embodiment of the invention, a purified nucleotide sequence is provided comprising cDNA, mRNA, anti-sense DNA or homologous DNA corresponding to the cDNA sequence of Sequence ID No.3.
In accordance with a further embodiment of the invention, is a purified nucleotide sequence sharing 95% homology to Sequence ID No.3 and encoding for human LyP 1 protein.
In accordance with a further embodiment is a substantially pure human LyP2 protein.
In accordance with a further embodiment of the invention is an amino acid sequence corresponding to the amino acid sequence of Sequence ID No.4.
In accordance with a further embodiment of the invention, a method is provided for altering the lymphoid cell differentiation pathway in which LyP 1 and/or LyP2 is active comprising administering to the cell an agent selected from the group consisting of;
(a) monoclonal or polyclonal antibodies specifically binding human LyP 1 or LyP2 protein;
(b) a polynucleotide antisense strand capable of hybridizing to human LyP 1 and gene or gene transcripts;
(c) an agent to alter phosphorylation of human LyP 1 or LyP2 protein;
(d) a composition comprising a mixture of (a) to (c).
In accordance with a further embodiment of the invention, a method is provided for identifying allelic variants or heterospecific homologues of a LyP 1 gene comprising (a) choosing a nucleic acid probe or primer capable of hybridizing to a human LyP 1 gene sequence under stringent hybridization conditions;
(b) mixing said probe or primer with a sample of nucleic acids which may contain a nucleic acid corresponding to the variant or homologue;
(c) detecting hybridization of the probe or primer to the nucleic acid corresponding to the variant of homologue.
In accordance with a further embodiment of the invention, a method is provided for producing antibodies which selectively bind to a human LyP 1 or LyP2 protein comprising the steps of administering an immunogenically effective amount of a human LyP 1 or LyP2 immunogen to an animal;
allowing the animal to produce antibodies to the immunogen; and obtaining the antibodies fiom the animal or fiom a cell culture derived therefrom.
In accordance with a further embodiment of the invention, a substantially pure antibody is provided which binds selectively to an antigenic determinant of a human LyP 1 or LyP2 protein.
In accordance with a further embodiment of the invention, a method is provided for identifying compounds modulating expression of a human LyP 1 gene comprising;
contacting a cell with a test candidate wherein the cell includes a regulatory region of a human LyPl gene operably joined to a coding region; and detecting a change in expression of the coding region.
In accordance with a further embodiment of the invention, a method is provided for altering T cell differentiation in lymphoid tissues, comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of an isolated antisense nucleotide sequence which hybridizes with human LyP 1 or LyP2 gene sequence; and a substantially pure monoclonal antibody which recognizes LyP 1 or LyP2 protein.
In accordance with a further embodiment of the invention, a pharmaceutical composition is provided comprising an active ingredient selected from the group consisting of an antisense sequence which hybridizes to a human LyP 1 nucleotide sequence or to a transcript of the sequence;
a substantially pure antibody which binds selectively to human LyP 1 or LyP2 protein and a pharmaceutically acceptable carrier;
a mimetic of human LyP 1 or LyP2 protein;
a functional analog of human LyPI or LyP2 protein;
an inhibitor of human LyP 1 or LyP2 protein activity; and an agent capable of altering the phosphorylation state of human LyP 1 or LyP2 protein.
In accordance with a further embodiment of the invention, a method is provided of screening for an agent useful in treating a disorder characterized by an abnormality in a phosphorylation signaling pathway of lymphoid cells, wherein the pathway involves an interaction between a human LyP 1 or LyP2 protein and a human LyP 1 or LyP2 activator, comprising screening potential agents for ability to disrupt or promote the interaction as an indication of a useful agent.
In accordance with a further aspect of the invention, a method is provided of preventing or treating a disorder in a mammal characterized by an abnormality in an intracellular phosphorylation signaling pathway of lymphoid cells, wherein the pathway involves an interaction between a human LyP 1 or LyP2 protein and a human LyP 1 or LyP2 substrate, comprising the step of disrupting or promoting said interaction in vivo.
In accordance with another aspect of the invention, a transgenic mouse model for various diseases involving abnormally activated lymphoid cells which comprises an animal which has in its genome a human gene encoding LyP mutated to manifest altered activation. The transgenic mouse may exhibit symptoms indicative of lymphoid cell disorders.
In accordance with another aspect of the invention, the LyP 1 or LyP2 protein can be used as a starting point for rational drug design to provide ligands, therapeutic drugs, inhibitors or other types of small chemical molecules.
Brief Description of the Drawings Certain embodiments of the invention are described, reference being made to the accompanying drawings, wherein:
Figure 1 shows a Schematic diagram of LyPl and LyP2 deduced from the cDNA clones. Boxes indicate the open reading frame, with thin lines representing the 5' and 3' untranslated regions. The six overlapping cDNA clones (bold black lines) obtained from a human thymus cDNA library are shown under the schematic structures of the cDNAs.
Figure 2 shows an alignment of LyPl and Z70PEP amino acid sequences. The PTPase domain is indicated by brackets. An arrow indicates the end of the amino acid sequence shared by LyP 1 and LyP2 and the beginning of the unique C-terminal sequence of LyP 1. The NXXY motif is indicated by line above the sequence. The four potential SH3 domain binding sites are also indicated (asterisks). A
consensus sequence is shown below the alignment.
Figure 3 demonstrates that LyP2 is a result of alternative splicing of the LyP
gene. A, schematic map of the PCR strategy used. Primer 1 corresponds to the last 20 nucleotides shared by both LyP 1 and LyP2 sequences, primer 2 to LyP2 untranslated area and primer 3 to the beginning of the novel LyP 1 sequence, immediately downstream of primer 1. (see also C). B. The results of the PCT
amplification on genomic DNA. Lane 1, DNA size markers, Lane 2, a product of
3.Skb was amplified with primers 1 and 3. Lane 3, is a product of 100bp was amplified with primers 1 and 2. C. Schematic map of LyP 1 splicing. The sequences before the vertical line represent the splice donor site, while the nucleotide sequences after it are the LyP 1 intronic sequence which code for the unique C-terminal seven amino acids, stop codon (asterisk) and untranslated sequence (lower case letters) of LyP 1. A white box represents the common cDNA sequence shared by LyP 1 and LyP2, the black and the light gray boxes representing the unique sequences of each cDNA (LyP 1 and LyP2 respectively).
Figure 4 shows the expression profile of LyP 1 transcripts. The size of RNA
markers are indicated in kb. A. Human tissues of various origin. B. Immune relevant human tissues.
Figure 5 shows in vivo translation of LyP 1 and LyP2 proteins, COS-7 cells were transiently transfected with HA-tagged LyP 1 and LyP2 cDNAs and protein expression analyzed by Western blotting with anti-HA tag antibodies. Lane 1, pCDNA3. Lane 2, pCDNA3 LyP 1. Lane 3, pCDNA3 LyP2. Molecular mass markers are shown in kDa.
Figure 6 shows the relative quantification of LyP 1 and LyP2 transcripts in thymocytes cDNA by competitive PCR. Different concentration of competitor DNA
were added to fixed amount of sample cDNA. The results of PCR amplification products of :A. 26 cycles with specific primers to LyPI B.35 cycles with specific primers to LyP2. The internal control concentrations are indicated below the pictures in Pico-Molar.
Figure 7 shows the localization of LyP 1 and LyP2 in transiently transfected COS-7 cells by immunofluorescence. COS-7 cells were transiently transfected with HA-tagged LyP 1 and LyP2 cDNAs and Immunofluorescence was performed using a monoclonal antibody against HA tag. Magnification 1000X. A. Cells transfected with HA-LyP2 cDNA. B. Cells transfected with HA-LyPI cDNA.
Figure 8 shows regional mapping of the LyP gene by fluorescence in situ hybridization to normal human lymphocyte chromosomes counterstained with DAPI.
Biotinylated cDNA probe was detected with avidin-fluorescein isothiocyanate (FITC).
Part of a representative metaphase preparation is shown to indicate the position of the LyP probe FISH signals visible as two yellow fluorescent spots on the p arm of chromosome 1. A DAPI banded chromosome 1 together with schematic ideogram is shown to indicate that the LyPl probe hybridizes to band 1p13.
Desscrintion of the Invention Two novel intracellular protein tyrosine phosphatase cDNA sequences have been isolated from a human thymus cDNA library, LyP 1 (Table One) and its splice variant, LyP2 (Table Two). The amino acid sequences of LyP 1 and LyP2 are shown in Tables 3 and 4, respectively. Sequence analysis of LyPl reveals significant homology with the marine phosphatase Z70PEP, an intracellular PTPase widely expressed in hematopoietic tissues ( 10). LyP 1 shares an overall 70% amino acid identity with Z70PEP (Fig. 2). While there is 89% identity between the catalytic domain of LyP 1 and Z70PEP, significantly less homology is observed within the non catalytic portion (61 %), which clearly contains a large area of unique sequence.
Within this area LyP, but not Z70PEP, contains an NXXY sequence (see Fig. 2);
when tyrosine phosphorylated this motif may be recognized by a phosphotyrosine binding (PTB) domain (29). PTB domains are found in several signal transduction adaptor proteins (eg, IRS-1, Shc), while the NXXY motif is found in several receptor tyrosine kinases and signaling pathway proteins (29,30). LyPl also contains four proline rich sequences (see Fig 2), forming putative PXXP and class II
(XPPLPXR) SH3 domain binding motifs (31). Indeed, a recent study has demonstrated association of a proline-rich motif (PPPLPERTP) of the closely related phosphatase, Z70PEP
with the SH3 domain of the protein tyrosine kinase pSO~sK (32).
The LyPl ORF codes for a protein of 808 amino acids. Hydropathy analysis indicates that LyP 1 contained no obvious signal sequence or hydrophobic segments and is therefore predicted to be an intracellular protein. The N-terminal region of the LyPl amino acid sequence contains a single phosphatase catalytic domain.
Sequence analysis revealed 70% overall amino acid identity between LyP 1 and the marine phosphatase Z70PEP (89% within the catalytic domain and 61 % within the non-catalytic portion); while the homology between the phosphatase domain of LyP 1 and other PTPases marine varies between 30 and 60%. On the basis of this analysis it was initially believed that LyP 1 may be a human homologue of the marine phosphatase Z70PEP, however, data presented herein suggests that LyP 1 represents a novel member of this phosphatase family.
The marine Z70PEP also possesses several consensus PEST sequences (hence its name [PEST)-domain Phosphatase) of as yet unclear function (10). PEST
sequences contain an unusually high percentage of proline (P), glutamic/aspartic acid (E/D), serine (S), and threonine(T) residues and have been identified in many proteins and were proposed to confer a high susceptibility to rapid degradation (33).
Early studies on the rapidly degraded enzyme orinithine decarboxylase provided support for this hypothesis (34), but such claim could not be substantiated for Z70PEP
(35) or for other PEST containing proteins (36,37). An analysis of the LyPl sequence using the program PEST-FIND (PC analysis software; Oxford Molecular Group, Oxford) indicated the presence of only a single PEST region (amino acids 702-736), while five were confirmed in Z70PEP. Thus despite the relatively high degree of homology between the catalytic domain of LyP 1 and Z70PEP, significant differences between the proteins emerge upon comparison of the other domains. In view of these results it is likely that LyPl is closely related to Z70PEP.
The pattern of LyPl expression observed by Northern blotting suggests that it is preferentially expressed in lymphoid cells (Fig. 4), particularly in thymocytes and mature B and T cells. A low level of LyP 1 expression was also seen in tissues rich in lymphoid infiltrates, such as the small intestine and appendix. This pattern of expression suggests that LyP 1 may play a role in the regulation of aspects of both early and Late states of T cell differentiation. The lack of expression in fetal liver tissue, which contains a large population of pre-B cells, may suggest a different role in the biology of B cell development. The mRNA expression of LyP l and its isoform, LyP2, was differentiated by the use of more specific probes. Lymphoid mRNAs hybridized with a probe specific for the unique C-terminal of LyPl revealed the same pattern of expression seen in Northern blots obtained by using a cDNA fragment common to both LyP forms (not shown). This suggests that LyP2 expression is extremely low, below the threshold of detection of Northern blotting. This suggestion was confirmed by semi-quantitative PCR comparison of LyP 1 and LyP2 expression.
In thymocytes the expression of LyP 1 was found to be 100 fold greater than LyP2 (Fig. 7). Similar results were obtained from other lymphoid cells (not shown).
LyP2 appears to be derived from alternative splicing of an intronic sequence.
A 3. Skb intronic sequence of LyP 1 was found to contain an alternative exon, coding for the C-terminal 7 amino acids of LyP2, and at least part of its 3' untranslated area (Fig.3). Consequently the 116 amino acid C-terminal of LyPl is replaced by 7 alternative amino acids in LyP2. Several studies have shown that such C-terminal diversity in cytophasmic PTPases can be generated by alternative splicing. The intracellular Drosophila PTPases gene DPTP61F produces two proteins with distinct COOH-terminal sequences (38), which determine the targeting of the alternative protein forms to either a cytoplasmic or nuclear compartment. Similarly, alternative splicing produces four forms of PTP-S (S 1-S4), a variant of the T cell phosphatase 39). These alternative forms perform significantly different functions, PTP-S2 and PTP-S4 demonstrating inherent differences in their substrate specificity, potential to bind DNA, and subcellular location; despite the fact that only the last 6 amino acids of PTP-S2 are replaced by an alternative C-terminal (34aa) in PTP-S4 (40). Thus, the creation of C-terminal diversity by alternative splicing in phosphatases appears to be a general mechanism of generating functional diversity.
The differences between the LyP 1 and LyP2 C-terminal sequences suggested that potentially, these phosphatases could be also directed to different subcellular compartments. However, through immunofluorescent staining of transiently transfected Cos-7 cells, it was determined that both LyP 1 and LyP2 show a similar pattern of diffuse cytophasmatic staining (Fig. 7)~. Interestingly, there is some question about the cellular localization of the closely related marine phosphatase, Z70PEP. While it has been demonstrated that Z70PEP localized to the nucleus in transfected Hela cells, (35) it has also been demonstrated that Z70PEP
localized outside the nucleus when transiently overexpressed in Cos-1 and B1-141 T cells (32).
The significance of the alternative C-terminal sequences of LyP 1 and LyP2 remains unclear, but there are several differences between the C-terminal tails that may be key in revealing functional divergence. The C-terminus of LyPl, but not LyP2, contains a consensus sequence XS/TPXK/R ('4'KTPGK'45) recognized by the p34~~'z kinase (41 ), a cell cycle regulatory kinase (42), suggesting that LyP
1 may be phosphorylated in a cell cycle dependent manner. LyP 1 also contains four potential SH3 domain binding sites, compared to a single motif in LyP2; suggesting the isoforms may interact with different sets of SH3 domains. Such differences, together with the major differences in the level of RNA expression, may point to participation in separate signaling pathways or alternatively, to differences in the regulation of their activity.
The expression of LyPl and LyP2 protein in lymphoid tissues suggests it may be of functional importance to these cells, perhaps in functional differentiation of T
cells and therefore these proteins may play a role in certain disorders of lymphoid origin namely, leukemia and auto immune disorders.
Using FISH analysis, the LyP gene was found to be localized to chromosome 1p13 (Fig. 8). This region is of particular interest because it is a common site of chromosomal rearrangement in both solid and hematopoietic cancer (47, 48). One such chromosomal rearrangement is a frequent alteration in the 1p13 region in chromosomally aberrant clones isolated from both patients with Hodgdin's (49, 50) and non Hodgkin's (51 ) lymphomas. Several lines of evidence already suggest that PTPases may act as a tumour suppression gene (2, 52). This raises the possibility of an association between an abnormality of the 1p13 locus in these patients and an alteration of LyP.
In another embodiment of the present invention expression of the LyP gene in heterologous cell systems can be used to demonstrate structure-function relationships as well as provide for cell lines for the purposes of drug screening. Ligating the LyP
DNA sequence into a plasmid expression vector to transfect cells is a useful method to test the proteins influence on various cellular biochemical parameters including the identification of substrates as well as activators and inhibitors of the phosphatase.
Plasmid expression vectors containing either the entire, or portions thereof, LyP 1 or LyP2 can be used in in vitro mutagenesis experiments which will identify portions of the protein crucial for regulatory function.
The DNA sequence can be manipulated in studies to understand the expression of the gene and its product, to achieve production of large quantities of the protein for filnctional analysis, for antibody production, and for patient therapy. The changes in the sequence may or may not alter the expression pattern in terms of relative quantities, tissue-specificity and functional properties. Partial or full-length DNA
sequences which encode for the LyP 1 and LyP2 protein, modified or unmodified, may be ligated to bacterial expression vectors. E. coli can be used using the T7 RNA
polymerase/promoter system using two plasmids or by labeling of plasmid-encoded proteins, or by expression by infection with M13 Phage mGPI-2. E. coli vectors can also be used with Phage lamba regulatory sequences, by fusion protein vectors (eg.
lacZ and trpE), by maltose-binding protein fusions, and by glutathione-S-transferase fusion proteins.
Alternatively, the LyPl or LyP2 protein can be expressed in insect cells using baculoviral vectors, or in mammalian cells using vaccinia virus. For expression in mammalian cells, the cDNA sequence may be ligated to heterologous promoters, such as the simian virus (SV40) promoter in the pSV2 vector and introduced into cells, such as COS cells to achieve transient or long-term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin and mycophoenolic acid.
The normal LyP DNA sequence can be altered using procedures such as restriction enzyme digestion, fill-in with DNA polymerise, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence alteration with the use of specific oligonucleotides together with PCR.
The cDNA sequence or portions thereof, or a mini gene consisting of a cDNA
with an intron and its own promoter, is introduced into eukaryotic expression vectors by conventional techniques. These vectors permit the transcription of the cDNA
in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation.
The endogenous LyP gene promoter can also be used. Different promoters within vectors have different activities which alters the level of expression of the cDNA. In addition, certain promoters can also modulate function such as the glucocorticoid-responsive promoter from the mouse mammary tumor virus.
Some of the vectors listed contain selectable markers or neo bacterial genes that permit isolation of cells by chemical selection. Stable long-term vectors can be maintained in cells as episomal, freely replicating entities by using regulatory elements of viruses. Cell lines can also be produced which have integrated the vector into the genomic DNA. In this manner, the gene product is produced on a continuous basis.
Vectors are introduced into recipient cells by various methods including calcium phosphate, strontium phosphate, electroporation, lipofection, DEAF
dextran, microinj ection, or by protoplast fusion. Alternatively, the cDNA can be introduced by infection using viral vectors.
Eukaryotic expression systems can be used for many studies of the LyP gene and gene products) including determination of proper expression and post-translational modifications for full biological activity, identifying regulatory elements located in the S' region of the LyP gene and their role in tissue regulation of protein expression, production of large amounts of the normal and mutant protein for isolation and purification, to use cells expressing the LyP 1 or LyP2 protein as a functional assay system for antibodies generated against the protein or to test effectiveness of pharmacological agents, or as a component of a signal transduction system, to study the function of the normal complete protein, specific portions of the protein, or of naturally occurnng and artificially produced mutant proteins.
Using the techniques mentioned, the expression vectors containing the LyP 1 or LyP2 cDNA sequence or portions thereof can be introduced into a variety of mammalian cells from other species or into non-mammalian cells.
The recombinant cloning vector, according to this invention, comprises the selected DNA of the DNA sequences of this invention for expression in a suitable host. The DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that LyP 1 or LyP2 protein can be expressed.
The expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof. The expression control sequence may be selected from the group consisting of the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of the fd coat protein, early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus, simian virus, 3-phosphoglycerate kinase promoter, yeast acid phosphatase promoters, yeast alpha-mating factors and combinations thereof.
The host cell which may be transfected with the vector of this invention may be selected from the group consisting of E. coli, pseudomonas, bacillus subtillus, bacillus stearothermophilus, or other bacili; other bacteria, yeast, fungi, insect, mouse or other animal, plant hosts, or human tissue cells.
In situ hybridization is a method used to detect the expression of LyP 1 and LyP2 protein. In situ hybridization relies upon the hybridization of a specifically labelled nucleic acid probe to the cellular RNA in individual cells or tissues.
Therefore, it allows the identification of mRNA within intact tissues, such as the brain. In this method, oligonucleotides corresponding to unique portions of the LyP
gene are used to detect specific mRNA species in the brain.
In this method a rat is anesthetized and transcardially perfused with cold PBS, followed by perfusion with a formaldehyde solution. The brain or other tissues is then removed, frozen in liquid nitrogen, and cut into thin micron sections. The sections are placed on slides and incubated in proteinase K. Following rinsing in DEP, water and ethanol, the slides are placed in prehybridization buffer. A radioactive probe corresponding to the primer is made by nick translation and incubated with the sectioned brain tissue. After incubation and air drying, the labeled areas are visualized by autoradiography. Dark spots on the tissue sample indicate hybridization of the probe with brain mRNA which demonstrates the expression of the protein.
Transgenic Animal Models The creation of transgenic animal models for abnormal lymphoid function characterized by altered LyP 1 or LyP2 activity is important to the understanding of the function of these phosphatases in intracellular signaling and for the testing of possible therapies for abnormal T cell activation and differentiation. In general, techniques of generating transgenic animals are widely accepted and practiced.
A
laboratory manual on the manipulation of the mouse embryo, for example, is available detailing standard laboratory techniques for the production of transgenic mice (41 ).
There are several ways in which to create an animal model in which the LyP
gene is expressed. One could simply generate a specific mutation in the mouse LyP
gene as one strategy. Secondly a wild type human LyP gene and/or a humanized marine gene could be inserted into the animals genome by homologous recombination. It is also possible to insert a mutant (single or multiple) human gene as genomic or minigene construct using wild type or mutant or artificial promoter elements. More commonly, and most preferred in the present invention, knock-out of the endogenous marine genes may be accomplished by the insertion of artificially modified fragments of the endogenous gene by homologous recombination. The modifications include insertion of mutant stop codons, the deletion of DNA
sequences, or the inclusion of recombination elements (lox p sites) recognized by enzymes such as Cre recombinase. Gene knockout produces homozygous mutant mice, which show symptoms or phenotype similar to those exhibited by a human.
In general, for gene knock-out, embryonic stem cells heterozygous for a knockout mutation in a gene of interest (ie. LyP gene) and homozygous for a marker gene (eg. coat colour) are transplanted into the blastocoel cavity of 4.5 day embryos homozygous for an alternate market. The early embryos then are implanted into a pseudopregnant female. Some of the resulting progeny are chimeras. Chimeric mice then are backcrossed. Intercrossing will eventually produce individuals homozygous for the disrupted allele that is, knockout mice. (Capecchi, MR. 1989. Science.
244:1299-1291 ).
To inactivate the LyP mouse gene chemical or x-ray mutagenesis of mouse gametes, followed by fertilization, can be applied. Heterozygous offspring can then be identified by Southern blotting to demonstrate loss of one allele by dosage, or failure to inherit one parental allele using RFLP markers.
To create a transgenic mouse, a mutant or normal version of the human LyP
gene can be inserted into a mouse germ line using standard techniques of oocyte microinj ection or transfection or microinj ection into stem cells.
Alternatively, if it is desired to inactivate or replace the endogenous LyP gene, homologous recombination using embryonic stem cells may be applied.
For oocyte inj ection, one or more copies of a mutant or normal LyP gene can be inserted into the pronucleus of a just-fertilized mouse oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The liveborn mice can then be screened for integrants using analysis of tail DNA for the presence of human LyP
gene sequences. The transgene can be either a complete genomic sequence inj ected as a YAC or chromosome fragment, a cDNA with either the natural promoter or a heterologous promoter, or a minigene containing a11 of the coding region and other elements found to be necessary for optimum expression.
Retroviral infection of early embryos can also be done to insert the human LyP 1 gene. In this method, the human LyP gene is inserted into a retroviral vector which is used to directly infect mouse embryos during the early stages of development to generate a chimera, some of which will lead to germline transmission.
Homologous recombination using stem cells allows for the screening of gene transfer cells to identify the rare homologous recombination events. Once identified, these can be used to generate chimeras by injection of mouse blastocysts, and a proportion of the resulting mice will show germline transmission from the recombinant line. This methodology is especially useful if inactivation of the human LyP gene is desired. For example, inactivation of the LyP gene can be done by designing a DNA fragment which contains sequences from a LyP exon flanking a selectable marker. Homologous recombination leads to the insertion of the marker sequences in the middle of an exon, inactivating the LyP gene. DNA analysis of individual clones can then be used to recognize the homologous recombination events.
This embodiment of the invention has the most significant commercial value as a mouse model for abnormal lymphoid cell activity and this may include disorders such as leukemia and autoimmune disorders..
Screening for Disease In another embodiment of the invention the knowledge of the human LyP
sequence provides for screening for various diseases involving abnormally activated or inactivated LyP 1 or LyP2 in which the activity defect is due to a mutant LvP gene.
Such defects may include, for example, leukemia which is associated with 22 known gene translocations one of which may involve mutated LyP. Other defects may include autoimmune disorders such as rheumatoid arthritis.
People with at a risk for a lymphoid disease or, individuals not previously known to be at risk, or people in general may be screened routinely using probes to detect the presence of a mutant LyP gene by a variety of techniques. Genomic DNA
used for the diagnosis may be obtained from body cells, such as those present in the blood, tissue biopsy, surgical specimen, or autopsy material. The DNA may be isolated and used directly for detection of a specific sequence or may be PCR
amplified prior to analysis. RNA or cDNA may also be used. To detect a specific DNA sequence hybridization using specific oligonucleotides, direct DNA
sequencing, restriction enzyme digest, RNase protection, chemical cleavage, and ligase-mediated detection are a11 methods which can be utilized. Oligonucleotides specific to mutant sequences can be chemically synthesized and labelled radioactively with isotopes, or non-radioactively using biotin tags, and hybridized to individual DNA samples immobilized on membranes or other solid-supports by dot-blot or transfer from gels after electrophoresis. The presence or absence of these mutant sequences are then visualized using methods such as autoradiography, fluorometry, or colorimetric reaction. Suitable PCR primers can be generated which are useful for example in amplifying portions of the subject sequence containing identified mutations.
Direct DNA sequencing reveals sequence differences between normal and mutant LyP DNA. Cloned DNA segments may be used as probes to detect specific DNA segments. PCR can be used to enhance the sensitivity of this method. PCR
is an enzymatic amplification directed by sequence-specific primers, and involves repeated cycles of heat denaturation of the DNA, annealing of the complementary primers and extension of the annealed primer with a DNA polymerise. This results in an exponential increase of the target DNA.
Other nucleotide sequence amplification techniques may be used, such as ligation-mediated PCR, anchored PCR and enzymatic amplification as would be understood by those skilled in the art.
Sequence alterations may also generate fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by gel-blot hybridization. DNA fragments carrying the site (normal or mutant) are detected by their increase or reduction in size, or by the increase or decrease of corresponding restriction fragment numbers. Genomic DNA samples may also be amplified by PCR prior to treatment with the appropriate restriction enzyme and the fragments of different sizes are visualized under UV light in the presence of ethidium bromide after gel electrophoresis.
Genetic testing based on DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels.
Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis. SmaII deletions may also be detected as changes in the migration pattern of DNA heteroduplexes in non-denaturing gel electrophoresis.
Alternatively, a single base substitution mutation may be detected based on differential primer length in PCR. The PCR products of the normal and mutant gene could be differentially detected in acrylamide gels.
Nuclease protection assays (S 1 or ligase-mediated) also reveal sequence changes at specific locations. Alternatively, to confirm or detect a polymorphism restriction mapping changes ligated PCR, ASO, REF-SSCP and SSCP may be used.
Both REF-SSCP and SSCP are mobility shift assays which are based upon the change in conformation due to mutations.
DNA fragments may also be visualized by methods in which the individual DNA samples are not immobilized on membranes. The probe and target sequences may be in solution or the probe sequence may be immobilized. Autoradiography, radioactive decay, spectrophotometry, and fluorometry may also be used to identify specific individual genotypes.
According to an embodiment of the invention, the portion of the DNA
segment that is informative for a mutation, can be amplified using PCR. The DNA
segment immediately surrounding a specific mutation acquired firom peripheral blood or other tissue samples from an individual can be screened using constructed oligonucleotide primers. This region would then be amplied by PCR, the products separated by electrophoresis, and transferred to membrane. Labelled probes are then hybridized to the DNA fragments and autoradiography performed.
In accordance with another embodiment of the present invention are antibodies which recognize epitopes within the LyP 1 or LyP2 protein and which can be raised to provide information on the characteristics of the protein as well as for any mutant LyP 1 or LyP2 protein. Generation of antibodies would enable the visualization of the protein in cells and tissues using Western blotting. In this technique, proteins are run on polyacrylamide gel and then transferred onto nitrocellulose membranes.
These membranes are then incubated in the presence of the antibody (primary), then following washing are incubated to a secondary antibody which is used for detection of the protein-primary antibody complex. Following repeated washing, the entire complex is visualized using colourimetric or chemiluminescent methods.
Antibodies to the LyPl or LyP2 protein also allow for the use of immunocytochemistry and immunofluorescence techniques in which the proteins can be visualized directly in cells and tissues. This is most helpful in order to establish the subcellular location of the protein and the tissue specificity of the protein.
In general, methods for the preparation of antibodies are well known (42). In order to prepare polyclonal antibodies, fusion proteins containing defined portions or all of the LyP 1 or LyP2 protein or specific LyP 1 or LyP2 generated mutants can be synthesized in bacteria by expression of corresponding DNA sequences in a suitable cloning vehicle. The protein can then be purified, coupled to a carrier protein and mixed with Freund's adjuvant (to help stimulate the antigenic response by the rabbits) and inj ected into rabbits or other laboratory animals. Alternatively, protein can be isolated from cultured cells expressing the protein. Following booster injections at bi-weekly intervals, the rabbits or other laboratory animals are then bled and the sera isolated. The sera can be used directly or purified prior to use, by affinity chromatography. The sera can then be used to probe protein extracts run on a polyacrylamide gel to identify the LyP 1 or LyP2 protein or mutant protein.
Alternatively, synthetic peptides can be made to the antigenic portions of these proteins and used to innoculate the animals.
To produce monoclonal LyPl or LyP2 antibodies, cells actively expressing the protein are cultured or isolated from tissues and the cell extracts isolated.
The extracts or recombinant protein extracts, containing the LyP 1 or LyP2 protein, are inj ected in Freund's adjuvant into mice. After being injected 9 times over a three week period, the mice spleens are removed and resuspended in phosphate buffered saline (PBS).
The spleen cells serve as a source of lymphocytes, some of which are producing antibody of the appropriate specificity. These are then fused with a permanently growing myeloma partner cell, and the products of the fusion are plated into a number of tissue culture wells in the presence of a selective agent such as HAT. The wells are then screened to identify those containing cells making useful antibody by ELISA.
These are then freshly plated. After a period of growth, these wells are again screened to identify antibody-producing cells. Several cloning procedures are carried out until over 90% of the wells contain single clones which are positive for antibody production. From this procedure a stable line of clones is established which produce the antibody. The monoclonal antibody can then be purified by affinity chromatography using Protein A Sepharose.
DrugScreening Assays In accordance with another embodiment of the present invention there is provided assays for screening upstream activators and downstream effectors of human LyP 1 or LyP2 protein. Cell culture systems, both cell and cell-free, in which the human LyP gene has been transfected and is being expressed can be tested with a number of agents to identify specific activators and substrates of the phosphatase through labelled phosphorylation studies of the protein in which phosphatase activity is quantitated. Such assays are also useful in identifying the downstream protein effects of such activation and their effects on transcription of various genes. Mutant forms of the human LyP can also be transfected into cell lines in order to study which specifically constructed mutations in the gene sequence which lead to altered activation of the phosphatase and eventually lead to alterations in T cell activation and differentiation.
Such culture systems enable the screening for pharmacological agents which will prevent activation of both normal and abnormally activated LyP as well as agents which will inhibit downstream cellular effects of the activated LyP 1 and LyP2 protein. Transfected culture systems also permit for the identification of phosphatase inhibitors which will be useful as therapeutic compositions for treating lymphoid cell disorders.
Therapies An important aspect of the biochemical studies using the genetic information of this invention is the development of therapies to circumvent or overcome the effect of abnormally activated LyP gene product, and thus prevent, treat, control serious symptoms or cure lymphoid cell associated disease. In view of the expression of the Lyp gene in a variety of lymphoid tissues one has to recognize that abnormally activated LyP may lead to a variety of lymphoid cell disorders such as leukemia and autoimmune disorders. Hence, in considering various therapies, it is understood that such therapies may be targeted at various lymphoid tissues where LyP 1 or LyP2 is abnormally expressed.
In accordance with another embodiment of the present invention there is provided gene therapy as another potential therapeutic approach in which normal copies of the LyP gene are introduced into patients to successfully code for normal LyP 1 or LyP2 protein in several different affected cell types. Mutated copies of the LyP gene in which the protein product is inactivated can also be introduced into patients. The gene must be delivered to those cells in a form in which it can be taken up and code for sufficient protein to provide effective function.
Alternatively, in some mutants it has been possible to prevent disease by introducing another copy of the homologous gene bearing a second mutation in that gene or to alter the mutation, or use another gene to block its effect.
Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression.
The targeted cells however must be able to divide and the expression of the levels of normal protein should be high. The full length LyP gene can be cloned into a retroviral vector and driven from its endogenous promoter or from the retroviral long terminal repeat or from a promoter specific for the target cell type of interest (such as lymphoid cells).
Other viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpesvirus such as Epstein-Barr virus.
Gene transfer could also be achieved using non-viral means requiring infection in vitro. This would include calcium phosphate, DEAF dextran, electroporation, and protoplast fusion. Liposomes may also be potentially beneficial for delivery of DNA
into a cell. Although these methods are available, many of these are lower efficiency.
Transplantation of normal genes or mutated genes which code for an inactive LyP 1 or LyP2 into a targetted affected area of the patient can also be useful therapy for leukemia or associated malignancies. In this procedure, a LyP gene is transferred into a cultivatable cell type such as lymphoid cells, either exogenously or endogenously to the patient. These cells are then injected serotologically into the disease affected tissue(s).
The invention also provides a method for reversing a transformed phenotype resulting fi om the abnormal expression of the LyP human gene sequence and/or hyperactivation of a LyP 1 or LyP2 protein product which is responsible for transformation of cells into a malignant phenotype such as leukemia. Antisense based strategies can be employed to explore gene function, inhibit gene function and as a basis for therapeutic drug design. The principle is based on the hypothesis that sequence specific suppression of gene expression can be achieved by intracellular hybridization between mRNA and a complementary anti-sense species. It is possible to synthesize anti-sense strand nucleotides that bind the sense strand of RNA
or DNA
with a high degree of specif city. The formation of a hybrid RNA duplex may interfere with the processing/transport/translation and/or stability of a target mRNA.
Hybridization is required for an antisense effect to occur. Antisense effects have been described using a variety of approaches including the use of antisense oligonucleotides, injection of antisense RNA, DNA and transfection of antisense RNA
expression vectors.
Therapeutic antisense nucleotides can be made as oligonucleotides or expressed nucleotides. Oligonucleotides are short single strands of DNA which are usually 15 to 20 nucleic acid bases long. Expressed nucleotides are made by an expression vector such as an adenoviral, retroviral or plasmid vector. The vector is administered to the cells in culture, or to a patient, whose cells then make the antisense nucleotide. Expression vectors can be designed to produce antisense RNA, which can vary in length from a few dozen bases to several thousand.
Antisense effects can be induced by contrbl (sense) sequences. The extent of phenotypic changes are highly variable. Phenotypic effects induced by antisense are based on changes in criteria such as biological endpoints, protein levels, protein activation measurement and target mRNA levels.
Multidrug resistance is a useful model for the study of molecular events associated with phenotypic changes due to antisense effects since the MDR
phenotype can be established by expression of a single gene mdrl (MDR gene) encoding P-glycoprotein (a 170 kDa membrane glycoprotein, ATP-dependent efflux pump).
In the present invention, mammalian cells in which the LyP human cDNA has been transfected and which express an abnormal phenotype, can be additionally transfected with anti-sense LyP (LyP 1 or LyP2) nucleotide DNA sequences which hybridize to the LyP gene in order to inhibit the transcription of the gene and reverse or reduce the abnormal phenotype. Alternatively, portions of the LyP gene can be targeted with an anti-sense LyP sequence specific for the kinase domains or the unique amino terminal sequence which may be responsible for the malignant phenotype. Expression vectors can be used as a model for anti-sense gene therapy to target the LyP which is expressed in abnormal cells. In this manner abnormal cells and tissues can be targeted while allowing healthy cells to survive. This may prove to be an effective treatment for cell abnormalities induced by LyP 1 or LyP2.
Immunotherapy is also possible for the treatment of certain lymphoid cell disease. Antibodies can be raised to a hyperactive LyP 1 or LyP2 protein (or portion thereof) and then be administered to bind or block the abnormal protein and its deliterious effects. Simultaneously, expression of the normal protein product could be encouraged. Administration could be in the form of a one time immunogenic preparation or vaccine immunization. An immunogenic composition may be prepared as inj ectables, as liquid solutions or emulsions. The LyP protein may be mixed with pharmaceutically acceptable excipients compatible with the protein. Such excipients may include water, saline, dextrose, glycerol, ethanol and combinations thereof. The immunogenic composition and vaccine may further contain auxiliarry substances such as emulsifying agents or adjuvants to enhance effectiveness. Immunogenic compositions and vaccines may be administered parenterally by inj ection subcutaneously or intramuscularly.
The immunogenic preparations and vaccines are administered in such amount as will be therapeutically effective, protective and immunogenic. Dosage depends on the route of administration and will vary according to the size of the host.
The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples. These examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in the form and substitution of equivalents are contemplated as circumstances may suggest or render expedient.
Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.
Examples The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.
Methods of molecular genetics, protein and peptide biochemistry and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.
Example 1 - Isolation of Novel Human PTPases. LyPl and LyP2 To identify new members of the PTPase gene family that are expressed in thymocytes, a PCT-based approach was used with degenerate oligonucleotides directed at conserved regions of the PTPase catalytic domain. A fragment of ~400bp was amplified from thymocyte cDNA and identified PCR amplified clones corresponding to seven different phosphatases. Six clones were identical to previously isolated human phosphatases:PTP-PEST,24 PTPIB,zS TCPTP,z6 HPTPb,6 CD45 and PTPMEG2.z' A seventh clone had no human homologue but was 90%
homologous to the marine phosphatase Z70PEP.'~ This clone was used to screen a human thymocyte cDNA library. The first screening isolated two overlapping clones, P 1 and P2 (Fig. l ). Clone P2 was used to isolate a further three overlapping clones P3-PS from the cDNA library. Assembly of the five overlapping clones revealed a single cDNA of 2300bp containing an open reading frame (ORF) of 2076bp, predicting a protein of 692 amino acids. The sequence surrounding the putative ATG/methionine start codon contained a purine (A) at position -3 and G at +4, both regarded as important criteria for an eucaryotic initiation site.32 The N-terminal region of the amino acid sequence (Fig 2) contained a single PTPase catalytic domain characterized by the conserved sequence motif (I/V)HCXXGXXRS/T. This sequence, thought to form the phosphate binding pocket for substrate, is found in all PTPases and is essential for their enzymatic activity. In addition to the S
overlapping clones a single kb clone was isolated (P6, Fig. l), with 200bp of its S'-end overlapping nucleotides 19S0-20SS of the complete cDNA previously isolated. However this was followed by an alternative 700bp, coding for an ORF totalling 2424bp. The long (30S6bp) and short (23S6bp) forms share nucleotides 1-2097 but code for alternative C-terminal sequence. These forms are designated LyPI and LyP2 respectively. LyP2 is an alternative spliced isoform of LyPI.
Pol~nerase chain reaction and subclonin~ of the PTPases clones.
Total RNA was prepared from thymocytes using Trizol reagent (Gibco-BRL).
First strand cDNA synthesis was performed with oligo-dt primer and Superscript II RT
(Gibco-BRL). This was used as a template for PCR amplification with Taq DNA
polymerase (Perkin Eliner Cetus) and the following degenerate primers:
PTP1-GCGGATCCTCIGA(C/T)TA(C/T)AT(A/C/T)AA(T/C)GC [sense, SEQ. ID NO:
5]
PTP2-GCGAATTCCCIACICCIGC(A/G)CT(G/A)CA(G/A)TG [antisense, SEQ. m N0:6].
These degenerate primers are designed to match two highly conserved sequences within PTPase catalytic domains, XDYIIVA and HCSAG/VG respectively. PCR was performed as follows: five cycles of 60sec. at 94 ~ C, 30 sec. at 37 ~ C and 60 sec. at 72 ~ C , and a further 25 cycles with an annealing temperature of 45 ~ C.
Fragments of -400bp were isolated, cloned and sequenced.
Isolation and Sequencin of LyPI and LyP2 cDNA clones.
A cDNA library from human thymocytes was screened with a [32P] labelled 430bp LYPI fragment obtained by PCR. Plaques were transferred to ICN Biotrans nylon filters and screened by hybridization at 65 ~ C in 5 x SSC, 5 x Denhart's solution, O.1 %SDS (22). Phage DNA was prepared from positive plaques, cDNA inserts were excised, subcloned into pUC-19, and sequenced. To obtain the complete LyP 1 cDNA, secondary and tertiary library screenings were performed with the l.3kb and 0.6kb partial cDNA clones isolated in the first screening (Fig. 1) . One clone (PS) from the second screening was found to contain the carboxyterminal sequence of the spliced form of LyPl (LyP2).
Example 2 - LyP2 is produced by alternative RNA splicing of the LyP 1 message.
To confirm the hypothesis that LyP2 was produced by alternative splicing of LyP 1 RNA, three oligonucleotides matching sequences around the putative splicing sites were used in PCR amplifications on a genomic DNA template (Fig.3A).
Oligonucleotide 1 corresponded to the common nucleotides 2076-2097 of LyPl and LyP2 (Fig 3), oligonucleotide 2 to LyP2 untranslated area adjacent to the stop codon (nucleotides 2150-2168), and olignucleotide 3 to LyPl sequence immediately downstream of primer 1 (nucleotides 2098-2120). The resultant PCR products are shown in Fig 3B. PCR amplification with primers 1 and 3 created an approximately 3.Skb DNA fragment, suggesting the presence of an intron between the primers.
However PCR with primers 1 and 2 resulted in a much smaller fragment of 100bp, the size expected from LyP2 cDNA sequence. Upon sequencing, the S' end sequence of the 3.Skb fragment was found to contain the alternative C-terminus, stop codon and untranslated nucleotide sequence of LyP2 (Fig 3C). This clearly demonstrated that LyP 1 and LyP2 are the alternatively spliced transcripts of a single gene.
While the 3.Skb intron is spliced out of the LYP1 form, this does not occur in the LyP2 isoform and as a result only 7 amino acids are added and an alternative stop codon is utilized.
Example 3 - Characterization of LyP 1 and LyP2 proteins To determine whether LyPI and LyP2 proteins are expressed at their predicted sizes or undergo processing in eukaryotic cells, the full length cDNAs were tagged at their 5' end with a haemagglutinin (HA) epitope and transfected into Cos-7 cells. The cDNAs of LyPI and LyP2 code for polypeptides of molecular weight (Mw) 92,000 and 78,000 respectively. On SDS-PAGE gel the molecular weights of the transfected proteins were close to the predicted values (Fig.S). Antibodies to the HA tag recognized a single protein with an apparent Mw of 96kDa in LyPI transfected cells and a single protein with an apparent molecular Mw of 80kDa in LyP2 transfectants, indicating that these phosphatases do not undergo significant post translation modifications.
Preferential Expression of LAP 1 transcripts in Hematopoietic Tissues and Cells Northern blot analysis of mRNA from various human tissues using a LyPI
cDNA probe revealed a major transcript of approximately 3.8kb in all of the lymphoid tissues examined (Fig.4). Substantial levels of LyP mRNA were detected in spleen, lymph node, peripheral leukocytes, tonsil B and T lymphocytes, and to a lesser degree in bone marrow. In contrast, LyP transcripts were not detected in prostate, ovary, testis fetal-liver or colon tissues. A low level of LyP expression could however be detected in the small intestine and appendix mucosa, presumably due to the presence of contaminating lymphocytes. LyP2 expression could not detected by Northern blot analysis using a probe to the last 21 specific nucleotides. Therefore its expression relative to LyPI was quantified by competitive PCR on polyA+-derived single strand thymocyte cDNA. The internal standards were constructed by deleting 140bp from both LyP 1 and LyP2 cDNAs. Co-amplification of the target cDNA with various concentration of internal control revealed that a concentration of 0.05 x 10~
pM control DNA was needed to produce equivalent amounts of LyP2 target and control PCR
product while S x 10~ PM of internal standard was required with specific primers to LyP 1 (Fig.6). These results suggest that the level of LyP 1 expression in thymocytes is approximately 100 fold greater than the level of LyP2 expression.
Northern blot analysis of LyPl and LyP2 RNA.
Total RNA was extracted from thymocytes using Trizol reagent (Gibco BRL).
Poly A+ RNA was isolated by two passages through an oligo(dt) column. 2~g of Poly A+ RNA per sample was electrophoresed in a 1 % agarose formaldehyde gel and capillary blotted onto nitrocellulose filters. Filters and a human multiple tissue poly A+
RNA northern blots (Clontech) were hybridized overnight at 42 ~ C with [32p]
labelled LyP cDNA probes in 50% formamide, 5 x SSC, 5 x Denhart's solution, 0.1% SDS, SOp.I
NaZHP04 pH 6.5, and denatured Salmon sperm DNA (100p,g/ml). Specifically, 2~g of poly A+ RNA from various human tissues was hybridized with a 1.3 kb cDNA probe common to both LyPl and LyP2 and exposed 7 days or 24 hr with Actin. After hybridization the final wash was performed in 0.2%SSC, O. 1%SDS at 55 ~ C
(22).
Relative uantification of LyP 1 and LyP2 mRNA by Competitive Polymerase Chain Reaction.
The relative levels of LyP 1 and LyP2 messenger RNA (mRNA) in thymocytes were quantified by competitive PCR using a synthetic cDNA as internal standard. This technique involves co-amplification of a target cDNA (produced from the corresponding mRNA by reverse transcription) and of the internal standard. The target cDNA
and the internal standard use the same primer sequence, but yield PCR products of different sizes that can be resolved on gel electrophoresis. In the exponential phase of the amplification, the amount of target cDNA can be quantified by comparison with the amplification of various amounts of the internal standard. The amount of target sequence in the sample is estimated by the amount of control producing an equivalent amounts of PCR products. The internal standards were constructed by deleting 140bp from both LyP 1 and LyP2 cDNAs, using two EcoRl sites found in position 1805 and 1945. PCR primers: The 5' primer for both LyP 1 and LyP2- corresponds to nucleotides 1660-1682 with the 3' primer for LyPI- corresponding to nucleotides 2425-2447, while the 3' primer for LyP2- corresponds to nucleotides 2075-2097. cDNA was prepared from oligo (dT) selected mRNA as described previously. Aliquots of thymus cDNA
were co amplified with varying amounts of internal standard for 26 cycles for LyP 1 and 35 cycles for LyP2. (denaturating 94 ~ C 30 sec., annealing at 54 ~ C and elongation 45 sec. at 72 ~ C). The PCR products (40p1) were electrophoresed on 1.2% agarose gel, stained with ethidium bromide and photographed. The possibility of genomic DNA
contamination in the RT PCR reaction was excluded with the appropriate controls.
Example 4 - Cellular localization of LvP 1 and LyP2 in Transfected Cos-7 cells In order to determine the cellular localization of the two phosphatases, the distribution of both LyP 1 and LyP2 was determined by indirect immunofluorescence in transiently transfected Cos-7 cells. An HA epitope was attached as a three tandem repeat to 5' end of both LyP 1 and LyP2 cDNAs in the pCDNA3 eukaryotic expression vector. 48 hours after transfection , cells were fixed and incubated with antibodies to the HA epitope. Cos-7 cells transfected with either LyP 1 and LyP2 displayed prominent perinuclear and cytoplasmatic staining but no staining of the nucleus (Fig.
7). No fluorescence was noted in Cos-7 cells transfected with vector alone. The pattern of staining suggests that both of these phosphatases are predominantly cytoplasmatic.
Cell preparation and cell lines.
Thymuses were obtained from children undergoing open heart surgery.
Mononuclear cells were isolated by Ficoll-Hypaque gradient. Adherent cells were removed by incubation to plastic dishes for 60 minutes at 37 ~ C. The resulting thymocytes are typically >95% CD3+. Lymphocytes were isolated from tonsil tissue by Ficoll-Hypaque centrifugation, following by rosetting with neuraminidase treated sheep red blood cells (RBC) to isolate T lymphocytes. After isolating rosettes by Ficoll-Hypaque gradient centrifugation, T cells were released with ACT treatment (0.75%
NH4C1 in 20 mmol/L Tris, pH 7.2) of the rosettes to lyse the red blood cells.
The buffy layer, containing the B cells, was washed three times with PBS. The resultant T
lymphocytes are typically 98% to 99% CD3+and the B lymphocytes are typically 97%
to 98.5 % CD 19+.
Transfection To examine the actual size of the expressed proteins LyP 1 and LyP2, cDNAs were inserted into the pCDNA3 eukaryotic expression vector (Invitrogen). An HA
epitope (YPYDVPDYA) derived firom the haemagglutinin protein of influenza virus, was inserted as three-tandem repeat at the S' end of the coding sequences of both LyP
forms. The constructs were verified by sequencing. Cos-7 cells were transfected with 5~g DNA and SOp,I of Lipofectamine (Gibco -BRL) for 5 hours according to the manufacture's instructions. 24 hours before transfection 0.5 xIO~ Cos-7 cells were plated on 60mm plates in Dulbaco's modified Eagle medium (DMEM) containing 10% fetal calf serum. To examine the cellular localization of the expressed proteins, Cos-7 cells were transfected with 2~,g DNA and 17p,1 of Lipofectamine for 5 hours, incubated on sterile cover slips in six well plates (0.3 x 10~ /plate) in DMEM containing 10% fetal calf serum for 48 hours and stained.
Western Blotting .
Cos-7 cells (0.5x 10~ /plate) were washed three times with cold PBS and solubilized in cold lysis buffer (20mM Tris pH 7.5, 150mM NaCI, 1mM
EDTA, 1% NP-40, 1mM PMSF). The lysates were cleared by centrifugation. SDS
sample buffer was added to the clarified lysates and resolved by 7% SDS-PAGE .
The proteins were electrophoretically transferred to Hybond-C super nitrocellulose membrane (Amersham Life Science). Membranes were blocked with 5% non fat milk and probed with HA monoclonal antibody from Blco-Berkely. Detection was performed with horseradish peroxidase conjugated sheep anti mouse purchased from (Amersham Life Science) and chemiluminescence reagent from Kirkeggard &Perry laboratories.
Indirect Immunofluorescence 48 hours post transfection Cos-7 cells were washed in PBS and fixed for 30 min at room temperature in 2% paraformaldehyde. Cell permeabilization was performed with 0.1 % Triton X100. After blocking non-specific sites with 5% Donkey serum, the cells were incubated for 60 min at room temperature with monoclonal anti HA
tag (1:1000 in PBS) from Blco-Berkely. The cells were washed and exposed for 45 min. to cy3 conjugated affinipure Donkey anti mouse IgG (1:l000 in PBS) from Jackson Immunoresearch Laboratories, Inc. After 3-4 washes immunoreactivity was detected by fluorescence microscopy.
Example 5 - Identifying the Chromosomal Location of Lyp A 1.8 kb LyP cDNA fragment was used as a probe to examine the chromosomal location of LyP. Biotynylated LyP probe was prepared by nick translation for fluorescence in situ (FISH) to normal human lymphocyte chromosomes (counterstained with propidium iodide and 4',6-diamidin-3-phenylindol-dihydrochloride, DAPI, according to published methods (43, 44)). The probe was detected with avidin-FITC.
Images of metaphase preparations were captured by thermoelectrically cooled charge coupled camera (Photometrics, Tucson, AZ). Separate images of DAPI banded chromosomes (45) and FITC targeted chromosomes were obtained and merged electronically using image analysis software (Yale University, New Haven, CT) and pseudo coloured blue (DAPI) and yellow (FITC) as described by Boyle et al., (44). The band assignment was determined by measuring the fractional chromosome length and by analyzing the banding pattern generated by the DAPI counterstained image (46).
References 1. Brautigan DL: Great expectations: protein tyrosine phosphatases in cell regulation. B.B.A, 1114: 63, 1992.
2. Klein G: The approaching era of the tumor suppressor genes. Science 238: 1539, 1987.
3. Denu JM, Stuckey JA, Saper MA, Dixon JE: Form and function in protein dephosphorylation. Cell 87: 36l, 1996.
Figure 4 shows the expression profile of LyP 1 transcripts. The size of RNA
markers are indicated in kb. A. Human tissues of various origin. B. Immune relevant human tissues.
Figure 5 shows in vivo translation of LyP 1 and LyP2 proteins, COS-7 cells were transiently transfected with HA-tagged LyP 1 and LyP2 cDNAs and protein expression analyzed by Western blotting with anti-HA tag antibodies. Lane 1, pCDNA3. Lane 2, pCDNA3 LyP 1. Lane 3, pCDNA3 LyP2. Molecular mass markers are shown in kDa.
Figure 6 shows the relative quantification of LyP 1 and LyP2 transcripts in thymocytes cDNA by competitive PCR. Different concentration of competitor DNA
were added to fixed amount of sample cDNA. The results of PCR amplification products of :A. 26 cycles with specific primers to LyPI B.35 cycles with specific primers to LyP2. The internal control concentrations are indicated below the pictures in Pico-Molar.
Figure 7 shows the localization of LyP 1 and LyP2 in transiently transfected COS-7 cells by immunofluorescence. COS-7 cells were transiently transfected with HA-tagged LyP 1 and LyP2 cDNAs and Immunofluorescence was performed using a monoclonal antibody against HA tag. Magnification 1000X. A. Cells transfected with HA-LyP2 cDNA. B. Cells transfected with HA-LyPI cDNA.
Figure 8 shows regional mapping of the LyP gene by fluorescence in situ hybridization to normal human lymphocyte chromosomes counterstained with DAPI.
Biotinylated cDNA probe was detected with avidin-fluorescein isothiocyanate (FITC).
Part of a representative metaphase preparation is shown to indicate the position of the LyP probe FISH signals visible as two yellow fluorescent spots on the p arm of chromosome 1. A DAPI banded chromosome 1 together with schematic ideogram is shown to indicate that the LyPl probe hybridizes to band 1p13.
Desscrintion of the Invention Two novel intracellular protein tyrosine phosphatase cDNA sequences have been isolated from a human thymus cDNA library, LyP 1 (Table One) and its splice variant, LyP2 (Table Two). The amino acid sequences of LyP 1 and LyP2 are shown in Tables 3 and 4, respectively. Sequence analysis of LyPl reveals significant homology with the marine phosphatase Z70PEP, an intracellular PTPase widely expressed in hematopoietic tissues ( 10). LyP 1 shares an overall 70% amino acid identity with Z70PEP (Fig. 2). While there is 89% identity between the catalytic domain of LyP 1 and Z70PEP, significantly less homology is observed within the non catalytic portion (61 %), which clearly contains a large area of unique sequence.
Within this area LyP, but not Z70PEP, contains an NXXY sequence (see Fig. 2);
when tyrosine phosphorylated this motif may be recognized by a phosphotyrosine binding (PTB) domain (29). PTB domains are found in several signal transduction adaptor proteins (eg, IRS-1, Shc), while the NXXY motif is found in several receptor tyrosine kinases and signaling pathway proteins (29,30). LyPl also contains four proline rich sequences (see Fig 2), forming putative PXXP and class II
(XPPLPXR) SH3 domain binding motifs (31). Indeed, a recent study has demonstrated association of a proline-rich motif (PPPLPERTP) of the closely related phosphatase, Z70PEP
with the SH3 domain of the protein tyrosine kinase pSO~sK (32).
The LyPl ORF codes for a protein of 808 amino acids. Hydropathy analysis indicates that LyP 1 contained no obvious signal sequence or hydrophobic segments and is therefore predicted to be an intracellular protein. The N-terminal region of the LyPl amino acid sequence contains a single phosphatase catalytic domain.
Sequence analysis revealed 70% overall amino acid identity between LyP 1 and the marine phosphatase Z70PEP (89% within the catalytic domain and 61 % within the non-catalytic portion); while the homology between the phosphatase domain of LyP 1 and other PTPases marine varies between 30 and 60%. On the basis of this analysis it was initially believed that LyP 1 may be a human homologue of the marine phosphatase Z70PEP, however, data presented herein suggests that LyP 1 represents a novel member of this phosphatase family.
The marine Z70PEP also possesses several consensus PEST sequences (hence its name [PEST)-domain Phosphatase) of as yet unclear function (10). PEST
sequences contain an unusually high percentage of proline (P), glutamic/aspartic acid (E/D), serine (S), and threonine(T) residues and have been identified in many proteins and were proposed to confer a high susceptibility to rapid degradation (33).
Early studies on the rapidly degraded enzyme orinithine decarboxylase provided support for this hypothesis (34), but such claim could not be substantiated for Z70PEP
(35) or for other PEST containing proteins (36,37). An analysis of the LyPl sequence using the program PEST-FIND (PC analysis software; Oxford Molecular Group, Oxford) indicated the presence of only a single PEST region (amino acids 702-736), while five were confirmed in Z70PEP. Thus despite the relatively high degree of homology between the catalytic domain of LyP 1 and Z70PEP, significant differences between the proteins emerge upon comparison of the other domains. In view of these results it is likely that LyPl is closely related to Z70PEP.
The pattern of LyPl expression observed by Northern blotting suggests that it is preferentially expressed in lymphoid cells (Fig. 4), particularly in thymocytes and mature B and T cells. A low level of LyP 1 expression was also seen in tissues rich in lymphoid infiltrates, such as the small intestine and appendix. This pattern of expression suggests that LyP 1 may play a role in the regulation of aspects of both early and Late states of T cell differentiation. The lack of expression in fetal liver tissue, which contains a large population of pre-B cells, may suggest a different role in the biology of B cell development. The mRNA expression of LyP l and its isoform, LyP2, was differentiated by the use of more specific probes. Lymphoid mRNAs hybridized with a probe specific for the unique C-terminal of LyPl revealed the same pattern of expression seen in Northern blots obtained by using a cDNA fragment common to both LyP forms (not shown). This suggests that LyP2 expression is extremely low, below the threshold of detection of Northern blotting. This suggestion was confirmed by semi-quantitative PCR comparison of LyP 1 and LyP2 expression.
In thymocytes the expression of LyP 1 was found to be 100 fold greater than LyP2 (Fig. 7). Similar results were obtained from other lymphoid cells (not shown).
LyP2 appears to be derived from alternative splicing of an intronic sequence.
A 3. Skb intronic sequence of LyP 1 was found to contain an alternative exon, coding for the C-terminal 7 amino acids of LyP2, and at least part of its 3' untranslated area (Fig.3). Consequently the 116 amino acid C-terminal of LyPl is replaced by 7 alternative amino acids in LyP2. Several studies have shown that such C-terminal diversity in cytophasmic PTPases can be generated by alternative splicing. The intracellular Drosophila PTPases gene DPTP61F produces two proteins with distinct COOH-terminal sequences (38), which determine the targeting of the alternative protein forms to either a cytoplasmic or nuclear compartment. Similarly, alternative splicing produces four forms of PTP-S (S 1-S4), a variant of the T cell phosphatase 39). These alternative forms perform significantly different functions, PTP-S2 and PTP-S4 demonstrating inherent differences in their substrate specificity, potential to bind DNA, and subcellular location; despite the fact that only the last 6 amino acids of PTP-S2 are replaced by an alternative C-terminal (34aa) in PTP-S4 (40). Thus, the creation of C-terminal diversity by alternative splicing in phosphatases appears to be a general mechanism of generating functional diversity.
The differences between the LyP 1 and LyP2 C-terminal sequences suggested that potentially, these phosphatases could be also directed to different subcellular compartments. However, through immunofluorescent staining of transiently transfected Cos-7 cells, it was determined that both LyP 1 and LyP2 show a similar pattern of diffuse cytophasmatic staining (Fig. 7)~. Interestingly, there is some question about the cellular localization of the closely related marine phosphatase, Z70PEP. While it has been demonstrated that Z70PEP localized to the nucleus in transfected Hela cells, (35) it has also been demonstrated that Z70PEP
localized outside the nucleus when transiently overexpressed in Cos-1 and B1-141 T cells (32).
The significance of the alternative C-terminal sequences of LyP 1 and LyP2 remains unclear, but there are several differences between the C-terminal tails that may be key in revealing functional divergence. The C-terminus of LyPl, but not LyP2, contains a consensus sequence XS/TPXK/R ('4'KTPGK'45) recognized by the p34~~'z kinase (41 ), a cell cycle regulatory kinase (42), suggesting that LyP
1 may be phosphorylated in a cell cycle dependent manner. LyP 1 also contains four potential SH3 domain binding sites, compared to a single motif in LyP2; suggesting the isoforms may interact with different sets of SH3 domains. Such differences, together with the major differences in the level of RNA expression, may point to participation in separate signaling pathways or alternatively, to differences in the regulation of their activity.
The expression of LyPl and LyP2 protein in lymphoid tissues suggests it may be of functional importance to these cells, perhaps in functional differentiation of T
cells and therefore these proteins may play a role in certain disorders of lymphoid origin namely, leukemia and auto immune disorders.
Using FISH analysis, the LyP gene was found to be localized to chromosome 1p13 (Fig. 8). This region is of particular interest because it is a common site of chromosomal rearrangement in both solid and hematopoietic cancer (47, 48). One such chromosomal rearrangement is a frequent alteration in the 1p13 region in chromosomally aberrant clones isolated from both patients with Hodgdin's (49, 50) and non Hodgkin's (51 ) lymphomas. Several lines of evidence already suggest that PTPases may act as a tumour suppression gene (2, 52). This raises the possibility of an association between an abnormality of the 1p13 locus in these patients and an alteration of LyP.
In another embodiment of the present invention expression of the LyP gene in heterologous cell systems can be used to demonstrate structure-function relationships as well as provide for cell lines for the purposes of drug screening. Ligating the LyP
DNA sequence into a plasmid expression vector to transfect cells is a useful method to test the proteins influence on various cellular biochemical parameters including the identification of substrates as well as activators and inhibitors of the phosphatase.
Plasmid expression vectors containing either the entire, or portions thereof, LyP 1 or LyP2 can be used in in vitro mutagenesis experiments which will identify portions of the protein crucial for regulatory function.
The DNA sequence can be manipulated in studies to understand the expression of the gene and its product, to achieve production of large quantities of the protein for filnctional analysis, for antibody production, and for patient therapy. The changes in the sequence may or may not alter the expression pattern in terms of relative quantities, tissue-specificity and functional properties. Partial or full-length DNA
sequences which encode for the LyP 1 and LyP2 protein, modified or unmodified, may be ligated to bacterial expression vectors. E. coli can be used using the T7 RNA
polymerase/promoter system using two plasmids or by labeling of plasmid-encoded proteins, or by expression by infection with M13 Phage mGPI-2. E. coli vectors can also be used with Phage lamba regulatory sequences, by fusion protein vectors (eg.
lacZ and trpE), by maltose-binding protein fusions, and by glutathione-S-transferase fusion proteins.
Alternatively, the LyPl or LyP2 protein can be expressed in insect cells using baculoviral vectors, or in mammalian cells using vaccinia virus. For expression in mammalian cells, the cDNA sequence may be ligated to heterologous promoters, such as the simian virus (SV40) promoter in the pSV2 vector and introduced into cells, such as COS cells to achieve transient or long-term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin and mycophoenolic acid.
The normal LyP DNA sequence can be altered using procedures such as restriction enzyme digestion, fill-in with DNA polymerise, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence alteration with the use of specific oligonucleotides together with PCR.
The cDNA sequence or portions thereof, or a mini gene consisting of a cDNA
with an intron and its own promoter, is introduced into eukaryotic expression vectors by conventional techniques. These vectors permit the transcription of the cDNA
in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation.
The endogenous LyP gene promoter can also be used. Different promoters within vectors have different activities which alters the level of expression of the cDNA. In addition, certain promoters can also modulate function such as the glucocorticoid-responsive promoter from the mouse mammary tumor virus.
Some of the vectors listed contain selectable markers or neo bacterial genes that permit isolation of cells by chemical selection. Stable long-term vectors can be maintained in cells as episomal, freely replicating entities by using regulatory elements of viruses. Cell lines can also be produced which have integrated the vector into the genomic DNA. In this manner, the gene product is produced on a continuous basis.
Vectors are introduced into recipient cells by various methods including calcium phosphate, strontium phosphate, electroporation, lipofection, DEAF
dextran, microinj ection, or by protoplast fusion. Alternatively, the cDNA can be introduced by infection using viral vectors.
Eukaryotic expression systems can be used for many studies of the LyP gene and gene products) including determination of proper expression and post-translational modifications for full biological activity, identifying regulatory elements located in the S' region of the LyP gene and their role in tissue regulation of protein expression, production of large amounts of the normal and mutant protein for isolation and purification, to use cells expressing the LyP 1 or LyP2 protein as a functional assay system for antibodies generated against the protein or to test effectiveness of pharmacological agents, or as a component of a signal transduction system, to study the function of the normal complete protein, specific portions of the protein, or of naturally occurnng and artificially produced mutant proteins.
Using the techniques mentioned, the expression vectors containing the LyP 1 or LyP2 cDNA sequence or portions thereof can be introduced into a variety of mammalian cells from other species or into non-mammalian cells.
The recombinant cloning vector, according to this invention, comprises the selected DNA of the DNA sequences of this invention for expression in a suitable host. The DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that LyP 1 or LyP2 protein can be expressed.
The expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof. The expression control sequence may be selected from the group consisting of the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of the fd coat protein, early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus, simian virus, 3-phosphoglycerate kinase promoter, yeast acid phosphatase promoters, yeast alpha-mating factors and combinations thereof.
The host cell which may be transfected with the vector of this invention may be selected from the group consisting of E. coli, pseudomonas, bacillus subtillus, bacillus stearothermophilus, or other bacili; other bacteria, yeast, fungi, insect, mouse or other animal, plant hosts, or human tissue cells.
In situ hybridization is a method used to detect the expression of LyP 1 and LyP2 protein. In situ hybridization relies upon the hybridization of a specifically labelled nucleic acid probe to the cellular RNA in individual cells or tissues.
Therefore, it allows the identification of mRNA within intact tissues, such as the brain. In this method, oligonucleotides corresponding to unique portions of the LyP
gene are used to detect specific mRNA species in the brain.
In this method a rat is anesthetized and transcardially perfused with cold PBS, followed by perfusion with a formaldehyde solution. The brain or other tissues is then removed, frozen in liquid nitrogen, and cut into thin micron sections. The sections are placed on slides and incubated in proteinase K. Following rinsing in DEP, water and ethanol, the slides are placed in prehybridization buffer. A radioactive probe corresponding to the primer is made by nick translation and incubated with the sectioned brain tissue. After incubation and air drying, the labeled areas are visualized by autoradiography. Dark spots on the tissue sample indicate hybridization of the probe with brain mRNA which demonstrates the expression of the protein.
Transgenic Animal Models The creation of transgenic animal models for abnormal lymphoid function characterized by altered LyP 1 or LyP2 activity is important to the understanding of the function of these phosphatases in intracellular signaling and for the testing of possible therapies for abnormal T cell activation and differentiation. In general, techniques of generating transgenic animals are widely accepted and practiced.
A
laboratory manual on the manipulation of the mouse embryo, for example, is available detailing standard laboratory techniques for the production of transgenic mice (41 ).
There are several ways in which to create an animal model in which the LyP
gene is expressed. One could simply generate a specific mutation in the mouse LyP
gene as one strategy. Secondly a wild type human LyP gene and/or a humanized marine gene could be inserted into the animals genome by homologous recombination. It is also possible to insert a mutant (single or multiple) human gene as genomic or minigene construct using wild type or mutant or artificial promoter elements. More commonly, and most preferred in the present invention, knock-out of the endogenous marine genes may be accomplished by the insertion of artificially modified fragments of the endogenous gene by homologous recombination. The modifications include insertion of mutant stop codons, the deletion of DNA
sequences, or the inclusion of recombination elements (lox p sites) recognized by enzymes such as Cre recombinase. Gene knockout produces homozygous mutant mice, which show symptoms or phenotype similar to those exhibited by a human.
In general, for gene knock-out, embryonic stem cells heterozygous for a knockout mutation in a gene of interest (ie. LyP gene) and homozygous for a marker gene (eg. coat colour) are transplanted into the blastocoel cavity of 4.5 day embryos homozygous for an alternate market. The early embryos then are implanted into a pseudopregnant female. Some of the resulting progeny are chimeras. Chimeric mice then are backcrossed. Intercrossing will eventually produce individuals homozygous for the disrupted allele that is, knockout mice. (Capecchi, MR. 1989. Science.
244:1299-1291 ).
To inactivate the LyP mouse gene chemical or x-ray mutagenesis of mouse gametes, followed by fertilization, can be applied. Heterozygous offspring can then be identified by Southern blotting to demonstrate loss of one allele by dosage, or failure to inherit one parental allele using RFLP markers.
To create a transgenic mouse, a mutant or normal version of the human LyP
gene can be inserted into a mouse germ line using standard techniques of oocyte microinj ection or transfection or microinj ection into stem cells.
Alternatively, if it is desired to inactivate or replace the endogenous LyP gene, homologous recombination using embryonic stem cells may be applied.
For oocyte inj ection, one or more copies of a mutant or normal LyP gene can be inserted into the pronucleus of a just-fertilized mouse oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The liveborn mice can then be screened for integrants using analysis of tail DNA for the presence of human LyP
gene sequences. The transgene can be either a complete genomic sequence inj ected as a YAC or chromosome fragment, a cDNA with either the natural promoter or a heterologous promoter, or a minigene containing a11 of the coding region and other elements found to be necessary for optimum expression.
Retroviral infection of early embryos can also be done to insert the human LyP 1 gene. In this method, the human LyP gene is inserted into a retroviral vector which is used to directly infect mouse embryos during the early stages of development to generate a chimera, some of which will lead to germline transmission.
Homologous recombination using stem cells allows for the screening of gene transfer cells to identify the rare homologous recombination events. Once identified, these can be used to generate chimeras by injection of mouse blastocysts, and a proportion of the resulting mice will show germline transmission from the recombinant line. This methodology is especially useful if inactivation of the human LyP gene is desired. For example, inactivation of the LyP gene can be done by designing a DNA fragment which contains sequences from a LyP exon flanking a selectable marker. Homologous recombination leads to the insertion of the marker sequences in the middle of an exon, inactivating the LyP gene. DNA analysis of individual clones can then be used to recognize the homologous recombination events.
This embodiment of the invention has the most significant commercial value as a mouse model for abnormal lymphoid cell activity and this may include disorders such as leukemia and autoimmune disorders..
Screening for Disease In another embodiment of the invention the knowledge of the human LyP
sequence provides for screening for various diseases involving abnormally activated or inactivated LyP 1 or LyP2 in which the activity defect is due to a mutant LvP gene.
Such defects may include, for example, leukemia which is associated with 22 known gene translocations one of which may involve mutated LyP. Other defects may include autoimmune disorders such as rheumatoid arthritis.
People with at a risk for a lymphoid disease or, individuals not previously known to be at risk, or people in general may be screened routinely using probes to detect the presence of a mutant LyP gene by a variety of techniques. Genomic DNA
used for the diagnosis may be obtained from body cells, such as those present in the blood, tissue biopsy, surgical specimen, or autopsy material. The DNA may be isolated and used directly for detection of a specific sequence or may be PCR
amplified prior to analysis. RNA or cDNA may also be used. To detect a specific DNA sequence hybridization using specific oligonucleotides, direct DNA
sequencing, restriction enzyme digest, RNase protection, chemical cleavage, and ligase-mediated detection are a11 methods which can be utilized. Oligonucleotides specific to mutant sequences can be chemically synthesized and labelled radioactively with isotopes, or non-radioactively using biotin tags, and hybridized to individual DNA samples immobilized on membranes or other solid-supports by dot-blot or transfer from gels after electrophoresis. The presence or absence of these mutant sequences are then visualized using methods such as autoradiography, fluorometry, or colorimetric reaction. Suitable PCR primers can be generated which are useful for example in amplifying portions of the subject sequence containing identified mutations.
Direct DNA sequencing reveals sequence differences between normal and mutant LyP DNA. Cloned DNA segments may be used as probes to detect specific DNA segments. PCR can be used to enhance the sensitivity of this method. PCR
is an enzymatic amplification directed by sequence-specific primers, and involves repeated cycles of heat denaturation of the DNA, annealing of the complementary primers and extension of the annealed primer with a DNA polymerise. This results in an exponential increase of the target DNA.
Other nucleotide sequence amplification techniques may be used, such as ligation-mediated PCR, anchored PCR and enzymatic amplification as would be understood by those skilled in the art.
Sequence alterations may also generate fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by gel-blot hybridization. DNA fragments carrying the site (normal or mutant) are detected by their increase or reduction in size, or by the increase or decrease of corresponding restriction fragment numbers. Genomic DNA samples may also be amplified by PCR prior to treatment with the appropriate restriction enzyme and the fragments of different sizes are visualized under UV light in the presence of ethidium bromide after gel electrophoresis.
Genetic testing based on DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels.
Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis. SmaII deletions may also be detected as changes in the migration pattern of DNA heteroduplexes in non-denaturing gel electrophoresis.
Alternatively, a single base substitution mutation may be detected based on differential primer length in PCR. The PCR products of the normal and mutant gene could be differentially detected in acrylamide gels.
Nuclease protection assays (S 1 or ligase-mediated) also reveal sequence changes at specific locations. Alternatively, to confirm or detect a polymorphism restriction mapping changes ligated PCR, ASO, REF-SSCP and SSCP may be used.
Both REF-SSCP and SSCP are mobility shift assays which are based upon the change in conformation due to mutations.
DNA fragments may also be visualized by methods in which the individual DNA samples are not immobilized on membranes. The probe and target sequences may be in solution or the probe sequence may be immobilized. Autoradiography, radioactive decay, spectrophotometry, and fluorometry may also be used to identify specific individual genotypes.
According to an embodiment of the invention, the portion of the DNA
segment that is informative for a mutation, can be amplified using PCR. The DNA
segment immediately surrounding a specific mutation acquired firom peripheral blood or other tissue samples from an individual can be screened using constructed oligonucleotide primers. This region would then be amplied by PCR, the products separated by electrophoresis, and transferred to membrane. Labelled probes are then hybridized to the DNA fragments and autoradiography performed.
In accordance with another embodiment of the present invention are antibodies which recognize epitopes within the LyP 1 or LyP2 protein and which can be raised to provide information on the characteristics of the protein as well as for any mutant LyP 1 or LyP2 protein. Generation of antibodies would enable the visualization of the protein in cells and tissues using Western blotting. In this technique, proteins are run on polyacrylamide gel and then transferred onto nitrocellulose membranes.
These membranes are then incubated in the presence of the antibody (primary), then following washing are incubated to a secondary antibody which is used for detection of the protein-primary antibody complex. Following repeated washing, the entire complex is visualized using colourimetric or chemiluminescent methods.
Antibodies to the LyPl or LyP2 protein also allow for the use of immunocytochemistry and immunofluorescence techniques in which the proteins can be visualized directly in cells and tissues. This is most helpful in order to establish the subcellular location of the protein and the tissue specificity of the protein.
In general, methods for the preparation of antibodies are well known (42). In order to prepare polyclonal antibodies, fusion proteins containing defined portions or all of the LyP 1 or LyP2 protein or specific LyP 1 or LyP2 generated mutants can be synthesized in bacteria by expression of corresponding DNA sequences in a suitable cloning vehicle. The protein can then be purified, coupled to a carrier protein and mixed with Freund's adjuvant (to help stimulate the antigenic response by the rabbits) and inj ected into rabbits or other laboratory animals. Alternatively, protein can be isolated from cultured cells expressing the protein. Following booster injections at bi-weekly intervals, the rabbits or other laboratory animals are then bled and the sera isolated. The sera can be used directly or purified prior to use, by affinity chromatography. The sera can then be used to probe protein extracts run on a polyacrylamide gel to identify the LyP 1 or LyP2 protein or mutant protein.
Alternatively, synthetic peptides can be made to the antigenic portions of these proteins and used to innoculate the animals.
To produce monoclonal LyPl or LyP2 antibodies, cells actively expressing the protein are cultured or isolated from tissues and the cell extracts isolated.
The extracts or recombinant protein extracts, containing the LyP 1 or LyP2 protein, are inj ected in Freund's adjuvant into mice. After being injected 9 times over a three week period, the mice spleens are removed and resuspended in phosphate buffered saline (PBS).
The spleen cells serve as a source of lymphocytes, some of which are producing antibody of the appropriate specificity. These are then fused with a permanently growing myeloma partner cell, and the products of the fusion are plated into a number of tissue culture wells in the presence of a selective agent such as HAT. The wells are then screened to identify those containing cells making useful antibody by ELISA.
These are then freshly plated. After a period of growth, these wells are again screened to identify antibody-producing cells. Several cloning procedures are carried out until over 90% of the wells contain single clones which are positive for antibody production. From this procedure a stable line of clones is established which produce the antibody. The monoclonal antibody can then be purified by affinity chromatography using Protein A Sepharose.
DrugScreening Assays In accordance with another embodiment of the present invention there is provided assays for screening upstream activators and downstream effectors of human LyP 1 or LyP2 protein. Cell culture systems, both cell and cell-free, in which the human LyP gene has been transfected and is being expressed can be tested with a number of agents to identify specific activators and substrates of the phosphatase through labelled phosphorylation studies of the protein in which phosphatase activity is quantitated. Such assays are also useful in identifying the downstream protein effects of such activation and their effects on transcription of various genes. Mutant forms of the human LyP can also be transfected into cell lines in order to study which specifically constructed mutations in the gene sequence which lead to altered activation of the phosphatase and eventually lead to alterations in T cell activation and differentiation.
Such culture systems enable the screening for pharmacological agents which will prevent activation of both normal and abnormally activated LyP as well as agents which will inhibit downstream cellular effects of the activated LyP 1 and LyP2 protein. Transfected culture systems also permit for the identification of phosphatase inhibitors which will be useful as therapeutic compositions for treating lymphoid cell disorders.
Therapies An important aspect of the biochemical studies using the genetic information of this invention is the development of therapies to circumvent or overcome the effect of abnormally activated LyP gene product, and thus prevent, treat, control serious symptoms or cure lymphoid cell associated disease. In view of the expression of the Lyp gene in a variety of lymphoid tissues one has to recognize that abnormally activated LyP may lead to a variety of lymphoid cell disorders such as leukemia and autoimmune disorders. Hence, in considering various therapies, it is understood that such therapies may be targeted at various lymphoid tissues where LyP 1 or LyP2 is abnormally expressed.
In accordance with another embodiment of the present invention there is provided gene therapy as another potential therapeutic approach in which normal copies of the LyP gene are introduced into patients to successfully code for normal LyP 1 or LyP2 protein in several different affected cell types. Mutated copies of the LyP gene in which the protein product is inactivated can also be introduced into patients. The gene must be delivered to those cells in a form in which it can be taken up and code for sufficient protein to provide effective function.
Alternatively, in some mutants it has been possible to prevent disease by introducing another copy of the homologous gene bearing a second mutation in that gene or to alter the mutation, or use another gene to block its effect.
Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression.
The targeted cells however must be able to divide and the expression of the levels of normal protein should be high. The full length LyP gene can be cloned into a retroviral vector and driven from its endogenous promoter or from the retroviral long terminal repeat or from a promoter specific for the target cell type of interest (such as lymphoid cells).
Other viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpesvirus such as Epstein-Barr virus.
Gene transfer could also be achieved using non-viral means requiring infection in vitro. This would include calcium phosphate, DEAF dextran, electroporation, and protoplast fusion. Liposomes may also be potentially beneficial for delivery of DNA
into a cell. Although these methods are available, many of these are lower efficiency.
Transplantation of normal genes or mutated genes which code for an inactive LyP 1 or LyP2 into a targetted affected area of the patient can also be useful therapy for leukemia or associated malignancies. In this procedure, a LyP gene is transferred into a cultivatable cell type such as lymphoid cells, either exogenously or endogenously to the patient. These cells are then injected serotologically into the disease affected tissue(s).
The invention also provides a method for reversing a transformed phenotype resulting fi om the abnormal expression of the LyP human gene sequence and/or hyperactivation of a LyP 1 or LyP2 protein product which is responsible for transformation of cells into a malignant phenotype such as leukemia. Antisense based strategies can be employed to explore gene function, inhibit gene function and as a basis for therapeutic drug design. The principle is based on the hypothesis that sequence specific suppression of gene expression can be achieved by intracellular hybridization between mRNA and a complementary anti-sense species. It is possible to synthesize anti-sense strand nucleotides that bind the sense strand of RNA
or DNA
with a high degree of specif city. The formation of a hybrid RNA duplex may interfere with the processing/transport/translation and/or stability of a target mRNA.
Hybridization is required for an antisense effect to occur. Antisense effects have been described using a variety of approaches including the use of antisense oligonucleotides, injection of antisense RNA, DNA and transfection of antisense RNA
expression vectors.
Therapeutic antisense nucleotides can be made as oligonucleotides or expressed nucleotides. Oligonucleotides are short single strands of DNA which are usually 15 to 20 nucleic acid bases long. Expressed nucleotides are made by an expression vector such as an adenoviral, retroviral or plasmid vector. The vector is administered to the cells in culture, or to a patient, whose cells then make the antisense nucleotide. Expression vectors can be designed to produce antisense RNA, which can vary in length from a few dozen bases to several thousand.
Antisense effects can be induced by contrbl (sense) sequences. The extent of phenotypic changes are highly variable. Phenotypic effects induced by antisense are based on changes in criteria such as biological endpoints, protein levels, protein activation measurement and target mRNA levels.
Multidrug resistance is a useful model for the study of molecular events associated with phenotypic changes due to antisense effects since the MDR
phenotype can be established by expression of a single gene mdrl (MDR gene) encoding P-glycoprotein (a 170 kDa membrane glycoprotein, ATP-dependent efflux pump).
In the present invention, mammalian cells in which the LyP human cDNA has been transfected and which express an abnormal phenotype, can be additionally transfected with anti-sense LyP (LyP 1 or LyP2) nucleotide DNA sequences which hybridize to the LyP gene in order to inhibit the transcription of the gene and reverse or reduce the abnormal phenotype. Alternatively, portions of the LyP gene can be targeted with an anti-sense LyP sequence specific for the kinase domains or the unique amino terminal sequence which may be responsible for the malignant phenotype. Expression vectors can be used as a model for anti-sense gene therapy to target the LyP which is expressed in abnormal cells. In this manner abnormal cells and tissues can be targeted while allowing healthy cells to survive. This may prove to be an effective treatment for cell abnormalities induced by LyP 1 or LyP2.
Immunotherapy is also possible for the treatment of certain lymphoid cell disease. Antibodies can be raised to a hyperactive LyP 1 or LyP2 protein (or portion thereof) and then be administered to bind or block the abnormal protein and its deliterious effects. Simultaneously, expression of the normal protein product could be encouraged. Administration could be in the form of a one time immunogenic preparation or vaccine immunization. An immunogenic composition may be prepared as inj ectables, as liquid solutions or emulsions. The LyP protein may be mixed with pharmaceutically acceptable excipients compatible with the protein. Such excipients may include water, saline, dextrose, glycerol, ethanol and combinations thereof. The immunogenic composition and vaccine may further contain auxiliarry substances such as emulsifying agents or adjuvants to enhance effectiveness. Immunogenic compositions and vaccines may be administered parenterally by inj ection subcutaneously or intramuscularly.
The immunogenic preparations and vaccines are administered in such amount as will be therapeutically effective, protective and immunogenic. Dosage depends on the route of administration and will vary according to the size of the host.
The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples. These examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in the form and substitution of equivalents are contemplated as circumstances may suggest or render expedient.
Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.
Examples The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.
Methods of molecular genetics, protein and peptide biochemistry and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.
Example 1 - Isolation of Novel Human PTPases. LyPl and LyP2 To identify new members of the PTPase gene family that are expressed in thymocytes, a PCT-based approach was used with degenerate oligonucleotides directed at conserved regions of the PTPase catalytic domain. A fragment of ~400bp was amplified from thymocyte cDNA and identified PCR amplified clones corresponding to seven different phosphatases. Six clones were identical to previously isolated human phosphatases:PTP-PEST,24 PTPIB,zS TCPTP,z6 HPTPb,6 CD45 and PTPMEG2.z' A seventh clone had no human homologue but was 90%
homologous to the marine phosphatase Z70PEP.'~ This clone was used to screen a human thymocyte cDNA library. The first screening isolated two overlapping clones, P 1 and P2 (Fig. l ). Clone P2 was used to isolate a further three overlapping clones P3-PS from the cDNA library. Assembly of the five overlapping clones revealed a single cDNA of 2300bp containing an open reading frame (ORF) of 2076bp, predicting a protein of 692 amino acids. The sequence surrounding the putative ATG/methionine start codon contained a purine (A) at position -3 and G at +4, both regarded as important criteria for an eucaryotic initiation site.32 The N-terminal region of the amino acid sequence (Fig 2) contained a single PTPase catalytic domain characterized by the conserved sequence motif (I/V)HCXXGXXRS/T. This sequence, thought to form the phosphate binding pocket for substrate, is found in all PTPases and is essential for their enzymatic activity. In addition to the S
overlapping clones a single kb clone was isolated (P6, Fig. l), with 200bp of its S'-end overlapping nucleotides 19S0-20SS of the complete cDNA previously isolated. However this was followed by an alternative 700bp, coding for an ORF totalling 2424bp. The long (30S6bp) and short (23S6bp) forms share nucleotides 1-2097 but code for alternative C-terminal sequence. These forms are designated LyPI and LyP2 respectively. LyP2 is an alternative spliced isoform of LyPI.
Pol~nerase chain reaction and subclonin~ of the PTPases clones.
Total RNA was prepared from thymocytes using Trizol reagent (Gibco-BRL).
First strand cDNA synthesis was performed with oligo-dt primer and Superscript II RT
(Gibco-BRL). This was used as a template for PCR amplification with Taq DNA
polymerase (Perkin Eliner Cetus) and the following degenerate primers:
PTP1-GCGGATCCTCIGA(C/T)TA(C/T)AT(A/C/T)AA(T/C)GC [sense, SEQ. ID NO:
5]
PTP2-GCGAATTCCCIACICCIGC(A/G)CT(G/A)CA(G/A)TG [antisense, SEQ. m N0:6].
These degenerate primers are designed to match two highly conserved sequences within PTPase catalytic domains, XDYIIVA and HCSAG/VG respectively. PCR was performed as follows: five cycles of 60sec. at 94 ~ C, 30 sec. at 37 ~ C and 60 sec. at 72 ~ C , and a further 25 cycles with an annealing temperature of 45 ~ C.
Fragments of -400bp were isolated, cloned and sequenced.
Isolation and Sequencin of LyPI and LyP2 cDNA clones.
A cDNA library from human thymocytes was screened with a [32P] labelled 430bp LYPI fragment obtained by PCR. Plaques were transferred to ICN Biotrans nylon filters and screened by hybridization at 65 ~ C in 5 x SSC, 5 x Denhart's solution, O.1 %SDS (22). Phage DNA was prepared from positive plaques, cDNA inserts were excised, subcloned into pUC-19, and sequenced. To obtain the complete LyP 1 cDNA, secondary and tertiary library screenings were performed with the l.3kb and 0.6kb partial cDNA clones isolated in the first screening (Fig. 1) . One clone (PS) from the second screening was found to contain the carboxyterminal sequence of the spliced form of LyPl (LyP2).
Example 2 - LyP2 is produced by alternative RNA splicing of the LyP 1 message.
To confirm the hypothesis that LyP2 was produced by alternative splicing of LyP 1 RNA, three oligonucleotides matching sequences around the putative splicing sites were used in PCR amplifications on a genomic DNA template (Fig.3A).
Oligonucleotide 1 corresponded to the common nucleotides 2076-2097 of LyPl and LyP2 (Fig 3), oligonucleotide 2 to LyP2 untranslated area adjacent to the stop codon (nucleotides 2150-2168), and olignucleotide 3 to LyPl sequence immediately downstream of primer 1 (nucleotides 2098-2120). The resultant PCR products are shown in Fig 3B. PCR amplification with primers 1 and 3 created an approximately 3.Skb DNA fragment, suggesting the presence of an intron between the primers.
However PCR with primers 1 and 2 resulted in a much smaller fragment of 100bp, the size expected from LyP2 cDNA sequence. Upon sequencing, the S' end sequence of the 3.Skb fragment was found to contain the alternative C-terminus, stop codon and untranslated nucleotide sequence of LyP2 (Fig 3C). This clearly demonstrated that LyP 1 and LyP2 are the alternatively spliced transcripts of a single gene.
While the 3.Skb intron is spliced out of the LYP1 form, this does not occur in the LyP2 isoform and as a result only 7 amino acids are added and an alternative stop codon is utilized.
Example 3 - Characterization of LyP 1 and LyP2 proteins To determine whether LyPI and LyP2 proteins are expressed at their predicted sizes or undergo processing in eukaryotic cells, the full length cDNAs were tagged at their 5' end with a haemagglutinin (HA) epitope and transfected into Cos-7 cells. The cDNAs of LyPI and LyP2 code for polypeptides of molecular weight (Mw) 92,000 and 78,000 respectively. On SDS-PAGE gel the molecular weights of the transfected proteins were close to the predicted values (Fig.S). Antibodies to the HA tag recognized a single protein with an apparent Mw of 96kDa in LyPI transfected cells and a single protein with an apparent molecular Mw of 80kDa in LyP2 transfectants, indicating that these phosphatases do not undergo significant post translation modifications.
Preferential Expression of LAP 1 transcripts in Hematopoietic Tissues and Cells Northern blot analysis of mRNA from various human tissues using a LyPI
cDNA probe revealed a major transcript of approximately 3.8kb in all of the lymphoid tissues examined (Fig.4). Substantial levels of LyP mRNA were detected in spleen, lymph node, peripheral leukocytes, tonsil B and T lymphocytes, and to a lesser degree in bone marrow. In contrast, LyP transcripts were not detected in prostate, ovary, testis fetal-liver or colon tissues. A low level of LyP expression could however be detected in the small intestine and appendix mucosa, presumably due to the presence of contaminating lymphocytes. LyP2 expression could not detected by Northern blot analysis using a probe to the last 21 specific nucleotides. Therefore its expression relative to LyPI was quantified by competitive PCR on polyA+-derived single strand thymocyte cDNA. The internal standards were constructed by deleting 140bp from both LyP 1 and LyP2 cDNAs. Co-amplification of the target cDNA with various concentration of internal control revealed that a concentration of 0.05 x 10~
pM control DNA was needed to produce equivalent amounts of LyP2 target and control PCR
product while S x 10~ PM of internal standard was required with specific primers to LyP 1 (Fig.6). These results suggest that the level of LyP 1 expression in thymocytes is approximately 100 fold greater than the level of LyP2 expression.
Northern blot analysis of LyPl and LyP2 RNA.
Total RNA was extracted from thymocytes using Trizol reagent (Gibco BRL).
Poly A+ RNA was isolated by two passages through an oligo(dt) column. 2~g of Poly A+ RNA per sample was electrophoresed in a 1 % agarose formaldehyde gel and capillary blotted onto nitrocellulose filters. Filters and a human multiple tissue poly A+
RNA northern blots (Clontech) were hybridized overnight at 42 ~ C with [32p]
labelled LyP cDNA probes in 50% formamide, 5 x SSC, 5 x Denhart's solution, 0.1% SDS, SOp.I
NaZHP04 pH 6.5, and denatured Salmon sperm DNA (100p,g/ml). Specifically, 2~g of poly A+ RNA from various human tissues was hybridized with a 1.3 kb cDNA probe common to both LyPl and LyP2 and exposed 7 days or 24 hr with Actin. After hybridization the final wash was performed in 0.2%SSC, O. 1%SDS at 55 ~ C
(22).
Relative uantification of LyP 1 and LyP2 mRNA by Competitive Polymerase Chain Reaction.
The relative levels of LyP 1 and LyP2 messenger RNA (mRNA) in thymocytes were quantified by competitive PCR using a synthetic cDNA as internal standard. This technique involves co-amplification of a target cDNA (produced from the corresponding mRNA by reverse transcription) and of the internal standard. The target cDNA
and the internal standard use the same primer sequence, but yield PCR products of different sizes that can be resolved on gel electrophoresis. In the exponential phase of the amplification, the amount of target cDNA can be quantified by comparison with the amplification of various amounts of the internal standard. The amount of target sequence in the sample is estimated by the amount of control producing an equivalent amounts of PCR products. The internal standards were constructed by deleting 140bp from both LyP 1 and LyP2 cDNAs, using two EcoRl sites found in position 1805 and 1945. PCR primers: The 5' primer for both LyP 1 and LyP2- corresponds to nucleotides 1660-1682 with the 3' primer for LyPI- corresponding to nucleotides 2425-2447, while the 3' primer for LyP2- corresponds to nucleotides 2075-2097. cDNA was prepared from oligo (dT) selected mRNA as described previously. Aliquots of thymus cDNA
were co amplified with varying amounts of internal standard for 26 cycles for LyP 1 and 35 cycles for LyP2. (denaturating 94 ~ C 30 sec., annealing at 54 ~ C and elongation 45 sec. at 72 ~ C). The PCR products (40p1) were electrophoresed on 1.2% agarose gel, stained with ethidium bromide and photographed. The possibility of genomic DNA
contamination in the RT PCR reaction was excluded with the appropriate controls.
Example 4 - Cellular localization of LvP 1 and LyP2 in Transfected Cos-7 cells In order to determine the cellular localization of the two phosphatases, the distribution of both LyP 1 and LyP2 was determined by indirect immunofluorescence in transiently transfected Cos-7 cells. An HA epitope was attached as a three tandem repeat to 5' end of both LyP 1 and LyP2 cDNAs in the pCDNA3 eukaryotic expression vector. 48 hours after transfection , cells were fixed and incubated with antibodies to the HA epitope. Cos-7 cells transfected with either LyP 1 and LyP2 displayed prominent perinuclear and cytoplasmatic staining but no staining of the nucleus (Fig.
7). No fluorescence was noted in Cos-7 cells transfected with vector alone. The pattern of staining suggests that both of these phosphatases are predominantly cytoplasmatic.
Cell preparation and cell lines.
Thymuses were obtained from children undergoing open heart surgery.
Mononuclear cells were isolated by Ficoll-Hypaque gradient. Adherent cells were removed by incubation to plastic dishes for 60 minutes at 37 ~ C. The resulting thymocytes are typically >95% CD3+. Lymphocytes were isolated from tonsil tissue by Ficoll-Hypaque centrifugation, following by rosetting with neuraminidase treated sheep red blood cells (RBC) to isolate T lymphocytes. After isolating rosettes by Ficoll-Hypaque gradient centrifugation, T cells were released with ACT treatment (0.75%
NH4C1 in 20 mmol/L Tris, pH 7.2) of the rosettes to lyse the red blood cells.
The buffy layer, containing the B cells, was washed three times with PBS. The resultant T
lymphocytes are typically 98% to 99% CD3+and the B lymphocytes are typically 97%
to 98.5 % CD 19+.
Transfection To examine the actual size of the expressed proteins LyP 1 and LyP2, cDNAs were inserted into the pCDNA3 eukaryotic expression vector (Invitrogen). An HA
epitope (YPYDVPDYA) derived firom the haemagglutinin protein of influenza virus, was inserted as three-tandem repeat at the S' end of the coding sequences of both LyP
forms. The constructs were verified by sequencing. Cos-7 cells were transfected with 5~g DNA and SOp,I of Lipofectamine (Gibco -BRL) for 5 hours according to the manufacture's instructions. 24 hours before transfection 0.5 xIO~ Cos-7 cells were plated on 60mm plates in Dulbaco's modified Eagle medium (DMEM) containing 10% fetal calf serum. To examine the cellular localization of the expressed proteins, Cos-7 cells were transfected with 2~,g DNA and 17p,1 of Lipofectamine for 5 hours, incubated on sterile cover slips in six well plates (0.3 x 10~ /plate) in DMEM containing 10% fetal calf serum for 48 hours and stained.
Western Blotting .
Cos-7 cells (0.5x 10~ /plate) were washed three times with cold PBS and solubilized in cold lysis buffer (20mM Tris pH 7.5, 150mM NaCI, 1mM
EDTA, 1% NP-40, 1mM PMSF). The lysates were cleared by centrifugation. SDS
sample buffer was added to the clarified lysates and resolved by 7% SDS-PAGE .
The proteins were electrophoretically transferred to Hybond-C super nitrocellulose membrane (Amersham Life Science). Membranes were blocked with 5% non fat milk and probed with HA monoclonal antibody from Blco-Berkely. Detection was performed with horseradish peroxidase conjugated sheep anti mouse purchased from (Amersham Life Science) and chemiluminescence reagent from Kirkeggard &Perry laboratories.
Indirect Immunofluorescence 48 hours post transfection Cos-7 cells were washed in PBS and fixed for 30 min at room temperature in 2% paraformaldehyde. Cell permeabilization was performed with 0.1 % Triton X100. After blocking non-specific sites with 5% Donkey serum, the cells were incubated for 60 min at room temperature with monoclonal anti HA
tag (1:1000 in PBS) from Blco-Berkely. The cells were washed and exposed for 45 min. to cy3 conjugated affinipure Donkey anti mouse IgG (1:l000 in PBS) from Jackson Immunoresearch Laboratories, Inc. After 3-4 washes immunoreactivity was detected by fluorescence microscopy.
Example 5 - Identifying the Chromosomal Location of Lyp A 1.8 kb LyP cDNA fragment was used as a probe to examine the chromosomal location of LyP. Biotynylated LyP probe was prepared by nick translation for fluorescence in situ (FISH) to normal human lymphocyte chromosomes (counterstained with propidium iodide and 4',6-diamidin-3-phenylindol-dihydrochloride, DAPI, according to published methods (43, 44)). The probe was detected with avidin-FITC.
Images of metaphase preparations were captured by thermoelectrically cooled charge coupled camera (Photometrics, Tucson, AZ). Separate images of DAPI banded chromosomes (45) and FITC targeted chromosomes were obtained and merged electronically using image analysis software (Yale University, New Haven, CT) and pseudo coloured blue (DAPI) and yellow (FITC) as described by Boyle et al., (44). The band assignment was determined by measuring the fractional chromosome length and by analyzing the banding pattern generated by the DAPI counterstained image (46).
References 1. Brautigan DL: Great expectations: protein tyrosine phosphatases in cell regulation. B.B.A, 1114: 63, 1992.
2. Klein G: The approaching era of the tumor suppressor genes. Science 238: 1539, 1987.
3. Denu JM, Stuckey JA, Saper MA, Dixon JE: Form and function in protein dephosphorylation. Cell 87: 36l, 1996.
4. Charbonneau H, Tonkes NK: 1002 protein phosphatases. Annu Rev Cell Biol 8:463, 1992.
5. Fischer EH, Charbonneau H, Tonks HK: Protein tyrosine phosphatases: A
diverse family of intracellular and transmembrane enzymes. Science 253: 401, l991.
diverse family of intracellular and transmembrane enzymes. Science 253: 401, l991.
6. Kruegert NX, Streuli M, Saito H: Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. EMBO J. 9: 3241, 1990.
7. Tonks NK, Neel BG: From form to function: Signaling by protein tyrosine phosphatases. Cell 87: 365, 1996.
8. Brady-Kanlnay SM, Tonks NK: Protein tyrosine phosphatases as adhesion receptors. Curr Opin Cell Biol 7:650, 1995.
9. Frangioni JV, Beahm PH, Shifirin V, Jost CA Neel BGL: The nontransmembrane tyrosine phosphatase PTP-IB locolized to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell 69:545, 1992.
10. Matthews RJ, Bowne DB, Flores E, Thomas ML: Characterization of hematopoietic intracellular protein tyrosine phosphatases: Description of phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol Cell Biol 12: 2396, 1992.
11. Ware MD, Rosten P, Damen JE, Liu L, Humphries RK, Krystal G: Cloning and characterization of Human SHIP, the 145-kD inositol S-phosphatase that associates with SHC after cytokine stimulation. Blood 88:2833, 1996.
12. Thomas ML: The leukocyte common antigen family. Annu Rev Immunol 7:
339, 1989.
339, 1989.
13. Justement LB, Campbell KS, Chien NC, Cambier JC: Regulation of B cell antigen receptor signal transduction and phosphorylation by CD45. Sceince 252:
1839, 1991.
1839, 1991.
14. Pingel JT, Thomas ML: Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferation. Cell 58: 10S5, 1989.
I5. Kishihara K, Penninger J, Wallace VA, Kundig TM, Kawai K, Wakeham A, Timms E, Pfeffer K, Ohashi PS, Tomas CF, Christopher JP, Mak TW: Normal B
lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficiet mice. Cell 74: 143, 1993.
16. Byth KF, Conroy LA, Howlett S, Smith AJH, May J, Alexander DR, Holmes N:CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CDS+ thymocytes, and in B cell maturation. J Exp Med 183:1707, 1996.
17. D'Ambrosio D, Hippen KL, Minskoff SA, Mellman l, Pani G, Siminovitch KA, Cambier: Recruitment and activation of PTP 1 C in negative regulation of antigen receptor signaling by FcBIII Science 268:293, 1995.
18. Yi T, Mui AL, Krystal G, Ihle JN: Hematopoietic cell phosphatase associates with the intreleukin (IL-3) receptor beta chain and down regulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol Cell Biol 13: 7577, 1993.
19. Raab M, Rudd CE: Hematopoietic cell phosphatase (HCP) regulates p56'~'' phosphorylation and ZAP-70 binding to T cell receptor chain. B.B.R.C 222:50, 1996.
20. Tsui HW, Siminovitch KA, Souza L, Tsui FWL: Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene.
Nature Geneties 4:124, 1993.
21. Zanke B, Suzuki H, Kishihara K, Mizzen L, Minden M, Pawson A, Mak TW:Cloning and expression of an inducible lymphoid-specific, protein tyrosine phosphatase (HePTPase). Eur. J. Immunol 22: 253, 1992.
22. Sambrook J, Fristsch EF,Maniatis T: Molecular cloning a laboratory manual, in Irwin N, Ford N, Ferguson M,Ockler M (eds): Cold Spring Harbor laboratory, New York, NY, l989.
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680, l970.
24. Yang Q, Co D, Sommercorn J, Tonks NK: Cloning and expression of PTP-PEST. A novel, human , nonrtransmembrane protein tyrosine phosphatase. J Biol Chem: 268, 1993.
25. Tonks NK, Diltz CD, Fischer EH: Purification of the major protein tyrosine phosphatases of human placenta. J Biol Chem 263: 6722, l988.
26. Cool DE, Tonks NK, Charbonneau H, Walsh KA, Fischer EH, Krebs EG:
cDNA isolated from a human T-cell library encodes a member of the protein -tyrosine -family. Pro Natl Acad Sci USA, 86: 52S7, 1989.
27. Gu M, York JD, Warshawsky I, Majerus PW: Identification, cloning, and expression of a cytosolic megakaryocyte protein tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1 Proc N atl Acad Sci USA 88: 5867, 1991.
28. Kozak M: Point mutation define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44: 283, 1986.
29. Laminet AA, Apell G, Conroy L, Kavanaugh WM: Affinity, specificity, and kinetics of the interaction of the SHC phosphotyrosine binding domain with asparagineX-X-phosphotyrosine motifs of growth factor receptors. J Biol Chem 271:264, l996.
30. Pawson T: Protein modules and sinalling networks. Nature 323:573, 1995.
31. Cohen GB, Ren R, Baltimore D: Modular binding domains in signal transduction proteins. Cell 80: 237, 1995.
32. Cloutier JF, Veillette A: Association of inhibitory tyrosine protein kinase p50~sx with protein tyrosine phosphatase PEP in T cells and other hematopoietic cells.
EMBO J 15:4909,1996.
33. Rogers S, Wells R, Rechsteiner M: Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. Science 234: 364, I986.
34. Loescher P, Pratt G, Rechsteiner M: The C terminus of mouse ornithine decarboxylase confers rapid degradation on dihydrofolate reductase. Support for the pest hypothesis- J Bio Chem 266: 11213, 1991.
35. Flores E, Roy G, Patel D, Shaw A, Thomas ML: Nuclear localization of the PEP protein tyrosine phosphatase. Mol Cell Bio 4: 4938, 1994.
36. Charest A, Wagner J, Shen SH, Tremblay ML: Murine thyrosine Phosphatase- PEST, a stable cytosolic protein tyrosine phosphtase- Biochem J.
308:42S, 199S.
37. Nixon PJ, Komenda J, Barber J, Deak Z, Vass I, Diner BA: Deletion of the PEST-like region of photosystem two modifies the QB-binding pocket but does not prevent rapid turnover of D 1. J B'ol Chem 270: 14919, 199S.
38. McLaughlin S, Dixon JE: Alternative splicing gives rise to a nuclear protein tyrosine phoshatase in Drosophila. J Biol Chem 268: 6839, 1993.
39. Reddy RS, Swarup G: Alternative splicing generates four different forms of a nontransmembrane protein tyrosine phosphatase MRNA. DNA Cell Biol 14:1007, 199S.
40. Kamatkar S, Radha V, Nambirajan S, Reddy RS, Swarup G: Two splice variants of thyrosine phosphatase differ in substrate specificity, DNA
binding, and subcellular location. J Biol Chem 271: 267SS, l996.
41. Peter MJ, Nakagawa M, Doree M, Labbe JC, Nigg EA: Identification of major nucleolar prteins as candidate of cdc2 kinase. Cell 60: 79l, 1990.
42. Krek W, Nigg EA: Mutations of p34~~Z phosphorylation sites induce prematuremitotic events in HeLa cells: evidence for a double block to p34"~Zkinase activation in vertebrates. EMBO J 10: 3331, 1991.
43. Lichter P, Tang C. J., Call K., Hermanson G., Evans G. A., Housman D., Ward D. C. High Resolution Mapping of Human Chromosome 11 by in situ Hybridization with Cosmid Clones. Science. 247: 64, 1990.
44. Boyle A. L., Feltquite D. M., Dracopoli N. C., Housman D. E., Ward D. C.
Rapid physical mapping of cloned DNA on banded mouse chromosomes by fluorescence in situ hybridization. Genomics. 12: 106, l992.
4S. Heng H., Tsui L. C. Modes of DAPI banding and simultaneous in situ hybridization. Chromosoma. l02: 32S, 1993.
46. Francke U. Digitized and differentially shaded human chromosome idegrams for genomic applications. Cytogene Cell Genet. 6S: 206, 1994.
47. Morns S. W., Valentine M. B., Shapiro D. N., Sublett J.E., Deaven L. L., Foust J. T., Robert W. M., Cerretti D. P., Look A. T. Reassignment of the human CSF1 gene to chromosome 1p13-p21. Blood. 78: 2013, l991.
48. Lion T., Harbott J., Barmier E., Ritterbach J., Jankovic M., Fink F. M., Stoj imirovic A., Hermann J., Riehm H. J. Lampert F., Ritter J., Koch H., Gadner H.
The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryotic leukemia in young children. Blood. 79: 3325, l992.
49. Schlegelberger B., Weber M. K. Himmler A., Baretels H., Sonnen R., Kuse R., Feller A. C., Grote W. Cytogenetic finding and results of combined immunophenotyping and karyotyping in Hodgkin's disease. Leukemia. 8: 72, 1994.
S0. Naumovski L., Utz P. J., Bergstrom S. K., Morgan R., Molina A., Toole J.
J., Glader B. E., McFall P., Weiss L. M., Warnke R., Smith S. D. SUP-HD 1: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma. Blood. 74: 2733, 1989.
51. Garry V. F., Danzl T. J., Tarone R., Griffith J., Cervenka J., Krueger L., Whortton E. B., Jr. Nelson R. L. Chromosome rearrangements in fumigant appliers:
possible relationship to non-Hodgkin's lymphoma risk. Cancer Epidemiol Biomarkers Prev. 1:287, 1992.
52. Li J., Yen C., Liaw D., Podsypaninia K., Bose S., Wang S. L, Puc J., Miliaresis C., Rodgers L., mcCombie R., Bigner S. H., Giovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wigler M. H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science.
257:
1943, 1997.
TCCCTCAACCTACTTATAGACTATTTTTCTTGCTCTGCAGCATGGACCAAAGAGAAATTCTGCA
GAAGTTCCTGGATGAGGCCCAAAGCAAGAAAATTACTAAAGAGGAGTTTGCCAATGAATTTCT
GAAGCTGAAAAGGCAATCTACCAAGTACAAGGCAGACAAAACCTATCCTACAACTGTGGCTG
AGAATGCCAAGAATATCAAGAAAAACAGATATAAGGATATTTTGCCCTATGATTATAGCCGGG
TAGAACTATCCCTGATAACCTCTGATGAGGATTCCAGCTACATCAATGCCAACTTCATTAAGG
GAGTTTATGGACCCAAGGCTTATATTGCCACCCAGGGTCCTTTATCTACAACCCTCCTGGACTT
CTGGAGGATGATTTGGGAATATAGTGTCCTTATCATTGTTATGGCATGCATGGAGTATGAAAT
GGGAAAGAAAAAGTGTGAGCGCTACTGGGCTGAGCCAGGAGAGATGCAGCTGGAATTTGGCC
CTTTCTCTGTATCCTGTGAAGCTGAAAAAAGGAAATCTGATTATATAATCAGGACTCTAAAAG
TTAAGTTCAATAGTGAAACTCGAACTATCTACCAGTTTCATTACAAGAATTGGCCAGACCATG
ATGTACCTTCATCTATAGACCCTATTCTTGAGCTCATCTGGGATGTACGTTGTTACCAAGAGGA
TGACAGTGTTCCCATATGCATTCACTGCAGTGCTGGCTGTGGAAGGACTGGTGTTATTTGTGCT
ATTGTTGATTATACATGGATGTTGCTAAAAGATGGGATAATTCCTGAGAACTTCAGTGTTTTCA
GTTTGATCCGGGAAATGCGGACACAGAGGCCTTCATTAGTTCAAACGCAGGAACAATATGAAC
TGGTCTACAATGCTGTATTAGAACTATTTAAGAGACAGATGGATGTTATCAGAGATAAACATT
CTGGAACAGAGAGTCAAGCAAAGCATTGTATTCCTGAGAAAAATCACACTCTCCAAGCAGACT
CTTATTCTCCTAATTTACCAAAAAGTACCACAAAAGCAGCAAAAATGATGAACCAACAAAGG
ACAAAAATGGAAATCAAAGAATCTTCTTCCTTTGACTTTAGGACTTCTGAAATAAGTGCAAAA
GAAGAGCTAGTTTTGCACCCTGCTAAATCAAGCACTTCTTTTGACTTTCTGGAGCTAAATTACA
GTTTTGACAAAAATGCTGACACAACCATGAAATGGCAGACAAAGGCATTTCCAATAGTTGGGG
AGCCTCTTCAGAAGCATCAAAGTTTGGATTTGGGCTCTCTTTTGTTTGAGGGATGTTCTAATTC
TAAACCTGTAAATGCAGCAGGAAGATATTTTAATTCAAAGGTGCCAATAACACGGACCAAATC
AACTCCTTTTGAATTGATACAGCAGAGAGAAACCAAGGAGGTGGACAGCAAGGAAAACTTTT
CTTATTTGGAATCTCAACCACATGATTCTTGTTTTGTAGAGATGCAGGCTCAAAAAGTAATGCA
TGTTTCTTCAGCAGAACTGAATTATTCACTGCCATATGACTCTAAACACCAAATACGTAATGCC
TCTAATGTAAAGCACCATGACTCTAGTGCTCTTGGTGTATATTCTTACATACCTTTAGTGGAAA
ATCCTTATITITCATCATGGCCTCCAAGTGGTACCAGTTCTAAGATGTCTCTTGATTTACCTGAG
AAGCAAGATGGAACTGTTTTTCCTTCTTCTCTGTTGCCAACATCCTCTACATCCCTCTTCTCTTA
TTACAATTCACATAGTTCTTTATCACTGAATTCTCCAACCAATATTTCCTCACTATTGAACCAG
GAGTCAGCTGTACTAGCAACTGCTCCAAGGATAGATGATGAAATCCCCCCTCCACTTCCTGTA
CGGACACCTGAATCATTTATTGTGGTTGAGGAAGCTGGAGAATTCTCACCAAATGTTCCCAAA
TCCTTATCCTCAGCTGTGAAGGTAAAAATTGGAACATCACTGGAATGGGGTGGAACATCTGAA
CCAAAGAAATTTGATGACTCTGTGATACTTAGACCAAGCAAGAGTGTAAAACTCCGAAGTCCT
AAATCAGAACTACATCAAGATCGTTCTTCTCCCCCACCTCCTCTCCCAGAAAGAACTCTAGAGT
CCTTCTTTCTTGCCGATGAAGATTGTATGCAGGCCCAATCTATAGAAACATATTCTACTAGCTA
TCCTGACACCATGGAAAATTCAACATCTTCAAAACAGACACTGAAGACTCCTGGAAAAAGTTT
CACAAGGAGTAAGAGTTTGAAAATTTTGCGAAACATGAAAAAGAGTATCTGTAATTCTTGCCC
ACCAAACAAGCCTGCAGAATCTGTTCAGTCAAATAACTCCAGCTCATTTCTGAATTTTGGTTTT
GCAAACCGTTTTTCAAAACCCAAAGGACCAAGGAATCCACCACCAACTTGGAATATTTAATAA
AACTCAGATTTATAATAATATGGGCTGCAAGTACACCTGCAAATAAAACTACTAGAATACTGC
TAGTTAAAATAAGTGCTCTATATGCATAATATGAAGATATGCTAATGTGTTAATAGCTTTTAAA
AGAAAAGCAAAATGCCAATAAGTGCCAGTTTTGCATTTTCATATCATTTGCATTGAGTTGAAA
ACTGCAAATAAAAGTTTGTCACTTGAGCTTATGTACAGAATGCTATATGAGAAACACTTTTAG
AATGGATTTATTTTTCATTTTTGCCAGTTATTTTTATTTTCTTTTACTTTTCTACATAAACATAAA
CTTCAAAAGGTTTGTAAGATTTGGATCTCAACTAATTTCTACATTGCCAGAATATACTATAAAA
AGTTA CTTACTTTGTGGGTTGCAATACAAACTGCTCTTGACAATGACTATTCC
CTGACAGTTATITITGCCTAAATGGAGTATACCTTGTAAATCTTCCCAAATGTTGTGGAAAACT
GGAATATTAAGAAAATGAGAAATTATATTTATTAGAATAAAATGTGCAAATAATGACAATTAT
TTGAATGTAACAAG
Table 1: Hunan LyPl cD:~lA sequence TCCCTCAACCTACTTATAGACTATTTTTCTTGCTCTGCAGCATGGACCAAAGAGAAATTCTGCA
GAAGTTCCTGGATGAGGCCCAAAGCAAGAAAATTACTAAAGAGGAGTTTGCCAATGAATTTCT
GAAGCTGAAAAGGCAATCTACCAAGTACAAGGCAGACAAAACCTATCCTACAACTGTGGCTG
AGAATGCCAAGAATATCAAGAAAAACAGATATAAGGATATTTTGCCCTATGATTATAGCCGGG
TAGAACTATCCCTGATAACCTCTGATGAGGATTCCAGCTACATCAATGCCAACTTCATTAAGG
GAGTTTATGGACCCAAGGCTTATATTGCCACCCAGGGTCCTTTATCTACAACCCTCCTGGACTT
CTGGAGGATGATTTGGGAATATAGTGTCCTTATCATTGTTATGGCATGCATGGAGTATGAAAT
GGGAAAGAAAAAGTGTGAGCGCTACTGGGCTGAGCCAGGAGAGATGCAGCTGGAATTTGGCC
CTTTCTCTGTATCCTGTGAAGCTGAAAAAAGGAAATCTGATTATATAATCAGGACTCTAAAAG
TTAAGTTCAATAGTGAAACTCGAACTATCTACCAGTTTCATTACAAGAATTGGCCAGACCATG
ATGTACCTTCATCTATAGACCCTATTCTTGAGCTCATCTGGGATGTACGTTGTTACCAAGAGGA
TGACAGTGTTCCCATATGCATTCACTGCAGTGCTGGCTGTGGAAGGACTGGTGTTATTTGTGCT
ATTGTTGATTATACATGGATGTTGCTAAAAGATGGGATAATTCCTGAGAACTTCAGTGTTTTCA
GTTTGATCCGGGAAATGCGGACACAGAGGCCTTCATTAGTTCAAACGCAGGAACAATATGAAC
TGGTCTACAATGCTGTATTAGAACTATTTAAGAGACAGATGGATGTTATCAGAGATAAACATT
CTGGAACAGAGAGTCAAGCAAAGCATTGTATTCCTGAGAAAAATCACACTCTCCAAGCAGACT
CTTATTCTCCTAATTTACCAAAAAGTACCACAAAAGCAGCAAAAATGATGAACCAACAAAGG
ACAAAAATGGAAATCAAAGAATCTTCTTCCTTTGACTTTAGGACTTCTGAAATAAGTGCAAAA
GAAGAGCTAGTTTTGCACCCTGCTAAATCAAGCACTTCTITTGACTTTCTGGAGCTAAATTACA
GTTTTGACAAAAATGCTGACACAACCATGAAATGGCAGACAAAGGCATTTCCAATAGTTGGGG
AGCCTCTTCAGAAGCATCAAAGTTTGGATTTGGGCTCTCTTTTGTTTGAGGGATGTTCTAATTC
TAAACCTGTAAATGCAGCAGGAAGATATTTTAATTCAAAGGTGCCAATAACACGGACCAAATC
AACTCCTTTTGAATTGATACAGCAGAGAGAAACCAAGGAGGTGGACAGCAAGGAAAACTTTT
CTTATTTGGAATCTCAACCACATGATTCTTGTTTTGTAGAGATGCAGGCTCAAAAAGTAATGCA
TGTTTCTTCAGCAGAACTGAATTATTCACTGCCATATGACTCTAAACACCAAATACGTAATGCC
TCTAATGTAAAGCACCATGACTCTAGTGCTCTTGGTGTATATTCTTACATACCTTTAGTGGAAA
ATCCTTATTTTTCATCATGGCCTCCAAGTGGTACCAGTTCTAAGATGTCTCTTGATTTACCTGAG
AAGCAAGATGGAACTGTTTTTCCTTCTTCTCTGTTGCCAACATCCTCTACATCCCTCTTCTCTTA
TTACAATTCACATAGTTCTTTATCACTGAATTCTCCAACCAATATTTCCTCACTATTGAACCAG
GAGTCAGCTGTACTAGCAACTGCTCCAAGGATAGATGATGAAATCCCCCCTCCACTTCCTGTA
CGGACACCTGAATCATTTATTGTGGTTGAGGAAGCTGGAGAATTCTCACCAAATGTTCCCAAA
TCCTTATCCTCAGCTGTGAAGGTAAAAATTGGAACATCACTGGAATGGGGTGGAACATCTGAA
CCAAAGAAA'ITTGATGACTCTGTGATACTTAGACCAAGCAAGAGTGTAAAACTCCGAAGTCCT
AAATCAGGTAAAAATTTCTCTTGGCTTTAGATGACATTTAGCCCTAAGATTGGAAGAATGGTT
CGTTAAGTTTAGAGTAATTCACTTCAGGAAGTTACTTGGTTCCCATAATAGCTTCCAGTATTCA
TTGATTTATTTCTGGCTTTCCCAGACTAGAAATTTTGTAAAGAGTCATGGGGGAAGCTAGGGCT
AACCAGAAAATAAAATAAAAATAATGGGATAAAAAATCGGAACTACTGTTTTCCCCCTAGTCG
GAGCACATCCGG
Table 2: Human LyP2 cDNA sequence MDQREILQKFLDEAQSKKITKEEFANEFLKLKRQSTKYKADKTYPTTVAENAKNIKKNRYKDILPY
DYSRVELSLITSDEDSSYINANFIKGVYGPKAYIATQGPLSTTLLDFWRMIWEYSVLIIVMACMEYE
MGKKKCERYWAEPGEMQLEFGPFSVSCEAEKRKSDYIIRTLKVKFNSETRTIYQFHYKNWPDHDV
PSSIDPILELIWDVRCYQEDDSVPICIHCSAGCGRTGVICAIVDYTWMLLKDGIIPENFSVFSLIREMR
TQRPSLVQTQEQYELVYNAVLELFKRQMDVIRDKHSGTESQAKHCIPEKNHTLQAD SYSPNLPKST
TKAAKMMNQQRTKMEIKESSSFDFRTSEISAKEELVLHPAKSSTSFDFLELNYSFDKNADTTMKW
QTKAFPIVGEPLQKHQSLDLGSLLFEGCSNSKPVNAAGRYFNSKVPITRTKSTPFELIQQRETKEVDS
KENFSYLESQPHDSCFVEMQAQKVMHVSSAELNYSLPYDSKHQIRNASNVKHIiDSSALGVYSYIP
LVENPYFSSWPPSGTSSKMSLDLPEKQDGTVFPSSLLPTSSTSLFSYYNSHSSLSLNSPTNISSLLNQE
SAVLATAPRIDDEIPPPLPVRTPESFIWEEAGEFSPNVPKSLSSAVKVKIGTSLEWGGTSEPKKFDDS
VILRPSKSVKLRSPKSELHQDRSSPPPPLPERTLESFFLADEDCMQAQSIETYSTSYPDTMENSTSSK
QTLKTPGKSFTRSKSLKILRNMKI~SICNSCPPNKPAESVQSNNSSSFLNFGFANRFSKPKGPRNPPPT
WNI
Table 3: l;yP1 Amino Acid Sequence MDQREILQKFLDEAQSKKITKEEFANEFLKLKRQSTKYKADKTYPTTVAENAKNIKKNRYKDILPY
DYSRVELSLITSDEDSSYINANFIKGVYGPKAYIATQGPLSTTLLDFWRMIWEYSVLIIVMACMEYE
MGKKKCERYWAEPGEMQLEFGPFSVSCEAEKRKSDYIIRTLKVKFNSETRTIYQFHYKNWPDHDV
PSSIDPILELIWDVRCYQEDDSVPICIHCSAGCGRTGVICAIVDYTWMLLKDGIIPENFSVFSLIREMR
TQRPSLVQTQEQYELVYNAVLELFKRQMDVIItDKHSGTESQAKHCIPEKNHTLQADSYSPNLPKST
TKAAICNIMNQQRTKMEIKESSSFDFRTSEISAKEELVLHPAKSSTSFDFLELNYSFDKNADTTMKW
QTKAFPIVGEPLQKHQSLDLGSLLFEGCSNSKPVNAAGRYFNSKVPITRTKSTPFELIQQRETKEVDS
KENFSYLESQPHDSCFVEMQAQKVMHVSSAELNYSLPYDSKHQIRNASNVKHHDSSALGVYSYIP
LVENPYFSSWPPSGTSSKMSLDLPEKQDGTVFPSSLLPTSSTSLFSYYNSDSSLSLNSPTNISSLLNQE
SAVLATAPRIDDEIPPPLPVRTPESFIWEEAGEFSPNVPKSLSSAVKVKIGTSLEWGGTSEPKKFDDS
VILRPSKSVKLRSPKSGKNFSWL
Table 4: LyP2 Amino Acid Sequence
I5. Kishihara K, Penninger J, Wallace VA, Kundig TM, Kawai K, Wakeham A, Timms E, Pfeffer K, Ohashi PS, Tomas CF, Christopher JP, Mak TW: Normal B
lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficiet mice. Cell 74: 143, 1993.
16. Byth KF, Conroy LA, Howlett S, Smith AJH, May J, Alexander DR, Holmes N:CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CDS+ thymocytes, and in B cell maturation. J Exp Med 183:1707, 1996.
17. D'Ambrosio D, Hippen KL, Minskoff SA, Mellman l, Pani G, Siminovitch KA, Cambier: Recruitment and activation of PTP 1 C in negative regulation of antigen receptor signaling by FcBIII Science 268:293, 1995.
18. Yi T, Mui AL, Krystal G, Ihle JN: Hematopoietic cell phosphatase associates with the intreleukin (IL-3) receptor beta chain and down regulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol Cell Biol 13: 7577, 1993.
19. Raab M, Rudd CE: Hematopoietic cell phosphatase (HCP) regulates p56'~'' phosphorylation and ZAP-70 binding to T cell receptor chain. B.B.R.C 222:50, 1996.
20. Tsui HW, Siminovitch KA, Souza L, Tsui FWL: Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene.
Nature Geneties 4:124, 1993.
21. Zanke B, Suzuki H, Kishihara K, Mizzen L, Minden M, Pawson A, Mak TW:Cloning and expression of an inducible lymphoid-specific, protein tyrosine phosphatase (HePTPase). Eur. J. Immunol 22: 253, 1992.
22. Sambrook J, Fristsch EF,Maniatis T: Molecular cloning a laboratory manual, in Irwin N, Ford N, Ferguson M,Ockler M (eds): Cold Spring Harbor laboratory, New York, NY, l989.
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680, l970.
24. Yang Q, Co D, Sommercorn J, Tonks NK: Cloning and expression of PTP-PEST. A novel, human , nonrtransmembrane protein tyrosine phosphatase. J Biol Chem: 268, 1993.
25. Tonks NK, Diltz CD, Fischer EH: Purification of the major protein tyrosine phosphatases of human placenta. J Biol Chem 263: 6722, l988.
26. Cool DE, Tonks NK, Charbonneau H, Walsh KA, Fischer EH, Krebs EG:
cDNA isolated from a human T-cell library encodes a member of the protein -tyrosine -family. Pro Natl Acad Sci USA, 86: 52S7, 1989.
27. Gu M, York JD, Warshawsky I, Majerus PW: Identification, cloning, and expression of a cytosolic megakaryocyte protein tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1 Proc N atl Acad Sci USA 88: 5867, 1991.
28. Kozak M: Point mutation define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44: 283, 1986.
29. Laminet AA, Apell G, Conroy L, Kavanaugh WM: Affinity, specificity, and kinetics of the interaction of the SHC phosphotyrosine binding domain with asparagineX-X-phosphotyrosine motifs of growth factor receptors. J Biol Chem 271:264, l996.
30. Pawson T: Protein modules and sinalling networks. Nature 323:573, 1995.
31. Cohen GB, Ren R, Baltimore D: Modular binding domains in signal transduction proteins. Cell 80: 237, 1995.
32. Cloutier JF, Veillette A: Association of inhibitory tyrosine protein kinase p50~sx with protein tyrosine phosphatase PEP in T cells and other hematopoietic cells.
EMBO J 15:4909,1996.
33. Rogers S, Wells R, Rechsteiner M: Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. Science 234: 364, I986.
34. Loescher P, Pratt G, Rechsteiner M: The C terminus of mouse ornithine decarboxylase confers rapid degradation on dihydrofolate reductase. Support for the pest hypothesis- J Bio Chem 266: 11213, 1991.
35. Flores E, Roy G, Patel D, Shaw A, Thomas ML: Nuclear localization of the PEP protein tyrosine phosphatase. Mol Cell Bio 4: 4938, 1994.
36. Charest A, Wagner J, Shen SH, Tremblay ML: Murine thyrosine Phosphatase- PEST, a stable cytosolic protein tyrosine phosphtase- Biochem J.
308:42S, 199S.
37. Nixon PJ, Komenda J, Barber J, Deak Z, Vass I, Diner BA: Deletion of the PEST-like region of photosystem two modifies the QB-binding pocket but does not prevent rapid turnover of D 1. J B'ol Chem 270: 14919, 199S.
38. McLaughlin S, Dixon JE: Alternative splicing gives rise to a nuclear protein tyrosine phoshatase in Drosophila. J Biol Chem 268: 6839, 1993.
39. Reddy RS, Swarup G: Alternative splicing generates four different forms of a nontransmembrane protein tyrosine phosphatase MRNA. DNA Cell Biol 14:1007, 199S.
40. Kamatkar S, Radha V, Nambirajan S, Reddy RS, Swarup G: Two splice variants of thyrosine phosphatase differ in substrate specificity, DNA
binding, and subcellular location. J Biol Chem 271: 267SS, l996.
41. Peter MJ, Nakagawa M, Doree M, Labbe JC, Nigg EA: Identification of major nucleolar prteins as candidate of cdc2 kinase. Cell 60: 79l, 1990.
42. Krek W, Nigg EA: Mutations of p34~~Z phosphorylation sites induce prematuremitotic events in HeLa cells: evidence for a double block to p34"~Zkinase activation in vertebrates. EMBO J 10: 3331, 1991.
43. Lichter P, Tang C. J., Call K., Hermanson G., Evans G. A., Housman D., Ward D. C. High Resolution Mapping of Human Chromosome 11 by in situ Hybridization with Cosmid Clones. Science. 247: 64, 1990.
44. Boyle A. L., Feltquite D. M., Dracopoli N. C., Housman D. E., Ward D. C.
Rapid physical mapping of cloned DNA on banded mouse chromosomes by fluorescence in situ hybridization. Genomics. 12: 106, l992.
4S. Heng H., Tsui L. C. Modes of DAPI banding and simultaneous in situ hybridization. Chromosoma. l02: 32S, 1993.
46. Francke U. Digitized and differentially shaded human chromosome idegrams for genomic applications. Cytogene Cell Genet. 6S: 206, 1994.
47. Morns S. W., Valentine M. B., Shapiro D. N., Sublett J.E., Deaven L. L., Foust J. T., Robert W. M., Cerretti D. P., Look A. T. Reassignment of the human CSF1 gene to chromosome 1p13-p21. Blood. 78: 2013, l991.
48. Lion T., Harbott J., Barmier E., Ritterbach J., Jankovic M., Fink F. M., Stoj imirovic A., Hermann J., Riehm H. J. Lampert F., Ritter J., Koch H., Gadner H.
The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryotic leukemia in young children. Blood. 79: 3325, l992.
49. Schlegelberger B., Weber M. K. Himmler A., Baretels H., Sonnen R., Kuse R., Feller A. C., Grote W. Cytogenetic finding and results of combined immunophenotyping and karyotyping in Hodgkin's disease. Leukemia. 8: 72, 1994.
S0. Naumovski L., Utz P. J., Bergstrom S. K., Morgan R., Molina A., Toole J.
J., Glader B. E., McFall P., Weiss L. M., Warnke R., Smith S. D. SUP-HD 1: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma. Blood. 74: 2733, 1989.
51. Garry V. F., Danzl T. J., Tarone R., Griffith J., Cervenka J., Krueger L., Whortton E. B., Jr. Nelson R. L. Chromosome rearrangements in fumigant appliers:
possible relationship to non-Hodgkin's lymphoma risk. Cancer Epidemiol Biomarkers Prev. 1:287, 1992.
52. Li J., Yen C., Liaw D., Podsypaninia K., Bose S., Wang S. L, Puc J., Miliaresis C., Rodgers L., mcCombie R., Bigner S. H., Giovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wigler M. H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science.
257:
1943, 1997.
TCCCTCAACCTACTTATAGACTATTTTTCTTGCTCTGCAGCATGGACCAAAGAGAAATTCTGCA
GAAGTTCCTGGATGAGGCCCAAAGCAAGAAAATTACTAAAGAGGAGTTTGCCAATGAATTTCT
GAAGCTGAAAAGGCAATCTACCAAGTACAAGGCAGACAAAACCTATCCTACAACTGTGGCTG
AGAATGCCAAGAATATCAAGAAAAACAGATATAAGGATATTTTGCCCTATGATTATAGCCGGG
TAGAACTATCCCTGATAACCTCTGATGAGGATTCCAGCTACATCAATGCCAACTTCATTAAGG
GAGTTTATGGACCCAAGGCTTATATTGCCACCCAGGGTCCTTTATCTACAACCCTCCTGGACTT
CTGGAGGATGATTTGGGAATATAGTGTCCTTATCATTGTTATGGCATGCATGGAGTATGAAAT
GGGAAAGAAAAAGTGTGAGCGCTACTGGGCTGAGCCAGGAGAGATGCAGCTGGAATTTGGCC
CTTTCTCTGTATCCTGTGAAGCTGAAAAAAGGAAATCTGATTATATAATCAGGACTCTAAAAG
TTAAGTTCAATAGTGAAACTCGAACTATCTACCAGTTTCATTACAAGAATTGGCCAGACCATG
ATGTACCTTCATCTATAGACCCTATTCTTGAGCTCATCTGGGATGTACGTTGTTACCAAGAGGA
TGACAGTGTTCCCATATGCATTCACTGCAGTGCTGGCTGTGGAAGGACTGGTGTTATTTGTGCT
ATTGTTGATTATACATGGATGTTGCTAAAAGATGGGATAATTCCTGAGAACTTCAGTGTTTTCA
GTTTGATCCGGGAAATGCGGACACAGAGGCCTTCATTAGTTCAAACGCAGGAACAATATGAAC
TGGTCTACAATGCTGTATTAGAACTATTTAAGAGACAGATGGATGTTATCAGAGATAAACATT
CTGGAACAGAGAGTCAAGCAAAGCATTGTATTCCTGAGAAAAATCACACTCTCCAAGCAGACT
CTTATTCTCCTAATTTACCAAAAAGTACCACAAAAGCAGCAAAAATGATGAACCAACAAAGG
ACAAAAATGGAAATCAAAGAATCTTCTTCCTTTGACTTTAGGACTTCTGAAATAAGTGCAAAA
GAAGAGCTAGTTTTGCACCCTGCTAAATCAAGCACTTCTTTTGACTTTCTGGAGCTAAATTACA
GTTTTGACAAAAATGCTGACACAACCATGAAATGGCAGACAAAGGCATTTCCAATAGTTGGGG
AGCCTCTTCAGAAGCATCAAAGTTTGGATTTGGGCTCTCTTTTGTTTGAGGGATGTTCTAATTC
TAAACCTGTAAATGCAGCAGGAAGATATTTTAATTCAAAGGTGCCAATAACACGGACCAAATC
AACTCCTTTTGAATTGATACAGCAGAGAGAAACCAAGGAGGTGGACAGCAAGGAAAACTTTT
CTTATTTGGAATCTCAACCACATGATTCTTGTTTTGTAGAGATGCAGGCTCAAAAAGTAATGCA
TGTTTCTTCAGCAGAACTGAATTATTCACTGCCATATGACTCTAAACACCAAATACGTAATGCC
TCTAATGTAAAGCACCATGACTCTAGTGCTCTTGGTGTATATTCTTACATACCTTTAGTGGAAA
ATCCTTATITITCATCATGGCCTCCAAGTGGTACCAGTTCTAAGATGTCTCTTGATTTACCTGAG
AAGCAAGATGGAACTGTTTTTCCTTCTTCTCTGTTGCCAACATCCTCTACATCCCTCTTCTCTTA
TTACAATTCACATAGTTCTTTATCACTGAATTCTCCAACCAATATTTCCTCACTATTGAACCAG
GAGTCAGCTGTACTAGCAACTGCTCCAAGGATAGATGATGAAATCCCCCCTCCACTTCCTGTA
CGGACACCTGAATCATTTATTGTGGTTGAGGAAGCTGGAGAATTCTCACCAAATGTTCCCAAA
TCCTTATCCTCAGCTGTGAAGGTAAAAATTGGAACATCACTGGAATGGGGTGGAACATCTGAA
CCAAAGAAATTTGATGACTCTGTGATACTTAGACCAAGCAAGAGTGTAAAACTCCGAAGTCCT
AAATCAGAACTACATCAAGATCGTTCTTCTCCCCCACCTCCTCTCCCAGAAAGAACTCTAGAGT
CCTTCTTTCTTGCCGATGAAGATTGTATGCAGGCCCAATCTATAGAAACATATTCTACTAGCTA
TCCTGACACCATGGAAAATTCAACATCTTCAAAACAGACACTGAAGACTCCTGGAAAAAGTTT
CACAAGGAGTAAGAGTTTGAAAATTTTGCGAAACATGAAAAAGAGTATCTGTAATTCTTGCCC
ACCAAACAAGCCTGCAGAATCTGTTCAGTCAAATAACTCCAGCTCATTTCTGAATTTTGGTTTT
GCAAACCGTTTTTCAAAACCCAAAGGACCAAGGAATCCACCACCAACTTGGAATATTTAATAA
AACTCAGATTTATAATAATATGGGCTGCAAGTACACCTGCAAATAAAACTACTAGAATACTGC
TAGTTAAAATAAGTGCTCTATATGCATAATATGAAGATATGCTAATGTGTTAATAGCTTTTAAA
AGAAAAGCAAAATGCCAATAAGTGCCAGTTTTGCATTTTCATATCATTTGCATTGAGTTGAAA
ACTGCAAATAAAAGTTTGTCACTTGAGCTTATGTACAGAATGCTATATGAGAAACACTTTTAG
AATGGATTTATTTTTCATTTTTGCCAGTTATTTTTATTTTCTTTTACTTTTCTACATAAACATAAA
CTTCAAAAGGTTTGTAAGATTTGGATCTCAACTAATTTCTACATTGCCAGAATATACTATAAAA
AGTTA CTTACTTTGTGGGTTGCAATACAAACTGCTCTTGACAATGACTATTCC
CTGACAGTTATITITGCCTAAATGGAGTATACCTTGTAAATCTTCCCAAATGTTGTGGAAAACT
GGAATATTAAGAAAATGAGAAATTATATTTATTAGAATAAAATGTGCAAATAATGACAATTAT
TTGAATGTAACAAG
Table 1: Hunan LyPl cD:~lA sequence TCCCTCAACCTACTTATAGACTATTTTTCTTGCTCTGCAGCATGGACCAAAGAGAAATTCTGCA
GAAGTTCCTGGATGAGGCCCAAAGCAAGAAAATTACTAAAGAGGAGTTTGCCAATGAATTTCT
GAAGCTGAAAAGGCAATCTACCAAGTACAAGGCAGACAAAACCTATCCTACAACTGTGGCTG
AGAATGCCAAGAATATCAAGAAAAACAGATATAAGGATATTTTGCCCTATGATTATAGCCGGG
TAGAACTATCCCTGATAACCTCTGATGAGGATTCCAGCTACATCAATGCCAACTTCATTAAGG
GAGTTTATGGACCCAAGGCTTATATTGCCACCCAGGGTCCTTTATCTACAACCCTCCTGGACTT
CTGGAGGATGATTTGGGAATATAGTGTCCTTATCATTGTTATGGCATGCATGGAGTATGAAAT
GGGAAAGAAAAAGTGTGAGCGCTACTGGGCTGAGCCAGGAGAGATGCAGCTGGAATTTGGCC
CTTTCTCTGTATCCTGTGAAGCTGAAAAAAGGAAATCTGATTATATAATCAGGACTCTAAAAG
TTAAGTTCAATAGTGAAACTCGAACTATCTACCAGTTTCATTACAAGAATTGGCCAGACCATG
ATGTACCTTCATCTATAGACCCTATTCTTGAGCTCATCTGGGATGTACGTTGTTACCAAGAGGA
TGACAGTGTTCCCATATGCATTCACTGCAGTGCTGGCTGTGGAAGGACTGGTGTTATTTGTGCT
ATTGTTGATTATACATGGATGTTGCTAAAAGATGGGATAATTCCTGAGAACTTCAGTGTTTTCA
GTTTGATCCGGGAAATGCGGACACAGAGGCCTTCATTAGTTCAAACGCAGGAACAATATGAAC
TGGTCTACAATGCTGTATTAGAACTATTTAAGAGACAGATGGATGTTATCAGAGATAAACATT
CTGGAACAGAGAGTCAAGCAAAGCATTGTATTCCTGAGAAAAATCACACTCTCCAAGCAGACT
CTTATTCTCCTAATTTACCAAAAAGTACCACAAAAGCAGCAAAAATGATGAACCAACAAAGG
ACAAAAATGGAAATCAAAGAATCTTCTTCCTTTGACTTTAGGACTTCTGAAATAAGTGCAAAA
GAAGAGCTAGTTTTGCACCCTGCTAAATCAAGCACTTCTITTGACTTTCTGGAGCTAAATTACA
GTTTTGACAAAAATGCTGACACAACCATGAAATGGCAGACAAAGGCATTTCCAATAGTTGGGG
AGCCTCTTCAGAAGCATCAAAGTTTGGATTTGGGCTCTCTTTTGTTTGAGGGATGTTCTAATTC
TAAACCTGTAAATGCAGCAGGAAGATATTTTAATTCAAAGGTGCCAATAACACGGACCAAATC
AACTCCTTTTGAATTGATACAGCAGAGAGAAACCAAGGAGGTGGACAGCAAGGAAAACTTTT
CTTATTTGGAATCTCAACCACATGATTCTTGTTTTGTAGAGATGCAGGCTCAAAAAGTAATGCA
TGTTTCTTCAGCAGAACTGAATTATTCACTGCCATATGACTCTAAACACCAAATACGTAATGCC
TCTAATGTAAAGCACCATGACTCTAGTGCTCTTGGTGTATATTCTTACATACCTTTAGTGGAAA
ATCCTTATTTTTCATCATGGCCTCCAAGTGGTACCAGTTCTAAGATGTCTCTTGATTTACCTGAG
AAGCAAGATGGAACTGTTTTTCCTTCTTCTCTGTTGCCAACATCCTCTACATCCCTCTTCTCTTA
TTACAATTCACATAGTTCTTTATCACTGAATTCTCCAACCAATATTTCCTCACTATTGAACCAG
GAGTCAGCTGTACTAGCAACTGCTCCAAGGATAGATGATGAAATCCCCCCTCCACTTCCTGTA
CGGACACCTGAATCATTTATTGTGGTTGAGGAAGCTGGAGAATTCTCACCAAATGTTCCCAAA
TCCTTATCCTCAGCTGTGAAGGTAAAAATTGGAACATCACTGGAATGGGGTGGAACATCTGAA
CCAAAGAAA'ITTGATGACTCTGTGATACTTAGACCAAGCAAGAGTGTAAAACTCCGAAGTCCT
AAATCAGGTAAAAATTTCTCTTGGCTTTAGATGACATTTAGCCCTAAGATTGGAAGAATGGTT
CGTTAAGTTTAGAGTAATTCACTTCAGGAAGTTACTTGGTTCCCATAATAGCTTCCAGTATTCA
TTGATTTATTTCTGGCTTTCCCAGACTAGAAATTTTGTAAAGAGTCATGGGGGAAGCTAGGGCT
AACCAGAAAATAAAATAAAAATAATGGGATAAAAAATCGGAACTACTGTTTTCCCCCTAGTCG
GAGCACATCCGG
Table 2: Human LyP2 cDNA sequence MDQREILQKFLDEAQSKKITKEEFANEFLKLKRQSTKYKADKTYPTTVAENAKNIKKNRYKDILPY
DYSRVELSLITSDEDSSYINANFIKGVYGPKAYIATQGPLSTTLLDFWRMIWEYSVLIIVMACMEYE
MGKKKCERYWAEPGEMQLEFGPFSVSCEAEKRKSDYIIRTLKVKFNSETRTIYQFHYKNWPDHDV
PSSIDPILELIWDVRCYQEDDSVPICIHCSAGCGRTGVICAIVDYTWMLLKDGIIPENFSVFSLIREMR
TQRPSLVQTQEQYELVYNAVLELFKRQMDVIRDKHSGTESQAKHCIPEKNHTLQAD SYSPNLPKST
TKAAKMMNQQRTKMEIKESSSFDFRTSEISAKEELVLHPAKSSTSFDFLELNYSFDKNADTTMKW
QTKAFPIVGEPLQKHQSLDLGSLLFEGCSNSKPVNAAGRYFNSKVPITRTKSTPFELIQQRETKEVDS
KENFSYLESQPHDSCFVEMQAQKVMHVSSAELNYSLPYDSKHQIRNASNVKHIiDSSALGVYSYIP
LVENPYFSSWPPSGTSSKMSLDLPEKQDGTVFPSSLLPTSSTSLFSYYNSHSSLSLNSPTNISSLLNQE
SAVLATAPRIDDEIPPPLPVRTPESFIWEEAGEFSPNVPKSLSSAVKVKIGTSLEWGGTSEPKKFDDS
VILRPSKSVKLRSPKSELHQDRSSPPPPLPERTLESFFLADEDCMQAQSIETYSTSYPDTMENSTSSK
QTLKTPGKSFTRSKSLKILRNMKI~SICNSCPPNKPAESVQSNNSSSFLNFGFANRFSKPKGPRNPPPT
WNI
Table 3: l;yP1 Amino Acid Sequence MDQREILQKFLDEAQSKKITKEEFANEFLKLKRQSTKYKADKTYPTTVAENAKNIKKNRYKDILPY
DYSRVELSLITSDEDSSYINANFIKGVYGPKAYIATQGPLSTTLLDFWRMIWEYSVLIIVMACMEYE
MGKKKCERYWAEPGEMQLEFGPFSVSCEAEKRKSDYIIRTLKVKFNSETRTIYQFHYKNWPDHDV
PSSIDPILELIWDVRCYQEDDSVPICIHCSAGCGRTGVICAIVDYTWMLLKDGIIPENFSVFSLIREMR
TQRPSLVQTQEQYELVYNAVLELFKRQMDVIItDKHSGTESQAKHCIPEKNHTLQADSYSPNLPKST
TKAAICNIMNQQRTKMEIKESSSFDFRTSEISAKEELVLHPAKSSTSFDFLELNYSFDKNADTTMKW
QTKAFPIVGEPLQKHQSLDLGSLLFEGCSNSKPVNAAGRYFNSKVPITRTKSTPFELIQQRETKEVDS
KENFSYLESQPHDSCFVEMQAQKVMHVSSAELNYSLPYDSKHQIRNASNVKHHDSSALGVYSYIP
LVENPYFSSWPPSGTSSKMSLDLPEKQDGTVFPSSLLPTSSTSLFSYYNSDSSLSLNSPTNISSLLNQE
SAVLATAPRIDDEIPPPLPVRTPESFIWEEAGEFSPNVPKSLSSAVKVKIGTSLEWGGTSEPKKFDDS
VILRPSKSVKLRSPKSGKNFSWL
Table 4: LyP2 Amino Acid Sequence
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2220853 CA2220853A1 (en) | 1998-01-16 | 1998-01-16 | Human lymphoid protein tyrosine phosphatases |
AU20432/99A AU2043299A (en) | 1998-01-16 | 1999-01-18 | Human lymphoid protein tyrosine phosphatases |
CA002318697A CA2318697A1 (en) | 1998-01-16 | 1999-01-18 | Human lymphoid protein tyrosine phosphatases |
PCT/CA1999/000038 WO1999036548A1 (en) | 1998-01-16 | 1999-01-18 | Human lymphoid protein tyrosine phosphatases |
US10/309,423 US20040006777A1 (en) | 1998-01-16 | 2002-12-03 | Human lymphoid protein tyrosine phosphatases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2220853 CA2220853A1 (en) | 1998-01-16 | 1998-01-16 | Human lymphoid protein tyrosine phosphatases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2220853A1 true CA2220853A1 (en) | 1999-07-16 |
Family
ID=4161759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2220853 Abandoned CA2220853A1 (en) | 1998-01-16 | 1998-01-16 | Human lymphoid protein tyrosine phosphatases |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2043299A (en) |
CA (1) | CA2220853A1 (en) |
WO (1) | WO1999036548A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1875900A3 (en) * | 2000-01-24 | 2010-07-21 | Genzyme Corporation | JAK/STAT pathway inhibitors and the use thereof for the treatment of osteoarthritis |
CA2326952A1 (en) * | 2000-11-27 | 2002-05-27 | The Hospital For Sick Children | T cell protein tyrosine phosphatase |
JP2009523404A (en) | 2003-01-30 | 2009-06-25 | アプレラ コーポレイション | Genetic polymorphism associated with rheumatoid arthritis, detection method and use thereof |
US20080199514A1 (en) * | 2004-07-09 | 2008-08-21 | The Burnham Institute | Functional Variant of Lymphoid Tyrosine Phosphatase is Associated with Autoimmune Disorders |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
WO2020198293A1 (en) * | 2019-03-25 | 2020-10-01 | Northshore University Health System | Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997035019A1 (en) * | 1996-03-22 | 1997-09-25 | Genentech, Inc. | Protein tyrosine phosphatases of hematopoietic cells |
CA2288221A1 (en) * | 1997-04-28 | 1998-11-05 | Sugen, Inc. | Diagnosis and treatment of phosphatase 0r kinase-related disorders |
-
1998
- 1998-01-16 CA CA 2220853 patent/CA2220853A1/en not_active Abandoned
-
1999
- 1999-01-18 WO PCT/CA1999/000038 patent/WO1999036548A1/en active Application Filing
- 1999-01-18 AU AU20432/99A patent/AU2043299A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999036548A1 (en) | 1999-07-22 |
AU2043299A (en) | 1999-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kerner et al. | Impaired expansion of mouse B cell progenitors lacking Btk | |
Liao et al. | Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk | |
NZ284612A (en) | Multiple tumour suppressor (mts) gene and its use in the diagnosis and treatment of cancer | |
US7700568B2 (en) | Uses of DNA-PK | |
JPH10513359A (en) | Inhibitors of cyclin-dependent kinases CDK4 and CDK6, InK4c-p18 and InK4d-p19, and uses thereof | |
JP4454670B2 (en) | Tumor suppressor called TS10Q23.3 | |
US6979724B2 (en) | Calcium channel proteins | |
US20080199443A1 (en) | Bone Morphogenetic Variants, Compositions and Methods of Treatment | |
CA2220853A1 (en) | Human lymphoid protein tyrosine phosphatases | |
US20040010812A1 (en) | Human hyaluronan receptor | |
US7479368B2 (en) | Method for detecting subjects having Paget's disease of bone | |
CA2253433A1 (en) | Mammalian regulator of nonsense-mediated rna decay | |
US6399298B1 (en) | Ku70—related methods | |
WO1999002724A2 (en) | Methods for identifying genes expressed in selected lineages, and a novel genes identified using the methods | |
US20040006777A1 (en) | Human lymphoid protein tyrosine phosphatases | |
US20100015654A1 (en) | Negative regulation of NK cell functions by EAT-2, a sap-related adaptor expressed in innate immune cells | |
US20060078550A1 (en) | Porcine fgl2 | |
CA2318697A1 (en) | Human lymphoid protein tyrosine phosphatases | |
CA2203706A1 (en) | Human jak2 kinase | |
US20030106076A1 (en) | Methods for identifying genes expressed in selected lineages, and a novel genes identified using the methods | |
US7491506B2 (en) | Inhibition of B-cell maturation and antibody production | |
WO2001051509A2 (en) | Shc-associated protein 140 (sap-140) | |
JP2003523181A (en) | DNA helicase, DNA molecule encoding human NHL | |
US20050130887A1 (en) | Genetic sequence related to bone diseases | |
Kim | Analysis of p38α during lymphocyte development and peripheral effector function/CD2AP haploinsufficiency is linked to glomerular disease susceptibility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |